



2016 ASH Annual Meeting & Exposition

*December 3-6, 2016
(Exhibits: December 3-4, 2016)
San Diego, California*

The American Society of Hematology (ASH) invites you to San Diego, California, for its 58th annual meeting. As the premier hematology event of the year, this meeting is an invaluable educational experience for all attendees.



Participation IUCT Oncopole - CRCT

67 posters

dont 3 communications orales et 9 posters 1^{er} auteur



INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE
Oncopole



Centre de Recherche en Cancérologie de Toulouse

Communications orales

1142 Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Myeloma: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy

Murielle Roussel, MD^{1*}, Valerie Lauwers-Cances, MD^{2*}, Nelly Robillard, PhD^{3*}, Karim Belhadj, MD^{4*}, Thierry Facon, MD, PhD⁵, Laurent Garderet, MD⁶, Martine Escoffre, MD^{7*}, Brigitte Pegourie, MD^{8*}, Lotfi Benboubker, MD, PhD^{9*}, Denis Caillot^{10*}, Cecile Fohrer, MD^{11*}, Philippe Moreau^{12*}, Xavier Leleu¹³, **Hervé Avet-Loiseau^{14*}** and **Michel Attal¹⁵**

¹Institut Universitaire du Cancer, toulouse, France

²USMR, service d'Epidemiologie, CHU Toulouse, TOULOUSE, France

³Hematology Laboratory, Nantes University Hospital, Nantes, France

⁴CHU Henri Mondor, Creteil, France

⁵Maladies du Sang, Lille University Hospital, Lille, France

⁶Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

⁷CHU Rennes, Rennes, France

⁸Hôpital A.Michallon, CHU Grenoble, Grenoble, France

⁹Hôpital Bretonneau Service Hématologie et Thérapies Cellulaires, Centre Régional de Cancérologie Henry Kaplan CHRU de Tours, Tours, France

¹⁰Hématologie Clinique, Dijon University Hospital, Dijon, France

¹¹HEMATOLOGY, CHU, Strasbourg, FRA

¹²Department of Hematology, Nantes University Hospital, Nantes, France

¹³ONCOLOGIE HEMATOLOGIQUE ET THERAPIE CELLULAIRE, CHU DE POITIERS, POITIERS, France

¹⁴IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

¹⁵Institut Universitaire du Cancer-Oncopole, Toulouse, France

762 The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study

Acute Lymphoblastic Leukemia: Clinical Studies

Program: Oral and Poster Abstracts

Type: Oral

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: New Approaches to Treatment Stratification and MRD Utilization

Françoise Huguet, MD^{1*}, Thibaut Leguay^{2*}, Xavier Thomas, MD, PhD³, Nicolas Boissel, MD, PhD⁴, Martine Escoffre-Barbe, MD^{5*}, Patrice Chevallier, MD, PhD^{6*}, Mathilde Hunault, MD, PhD^{7*}, Norbert Vey, MD⁸, Caroline Bonmati, MD^{9*}, Stéphane Leprêtre, MD^{10*}, Jean-Pierre Marolleau, MD, PhD¹¹, Thomas Pabst, MD, PhD^{12,13}, Philippe Rousselot, MD, PhD^{14*}, Agnès Buzyn, MD, PhD^{15*}, Jean-Yves Cahn, MD¹⁶, Véronique Lhéritier^{17*}, Marie C Béné, PharmD, PhD^{18*}, Vahid Asnafi, MD, PhD^{19*}, **Eric Delabesse, PharmD, PhD^{20*}**, Elizabeth Macintyre, MD, PhD²¹, Yves Chalandon, MD^{13,22}, Norbert Ifrah²³ and Hervé Dombret, MD^{24*}

¹Department of Hematology, Institut Universitaire de Cancérologie de Toulouse, Toulouse, France

²Hematology, Bordeaux University Hospital, Pessac, France

³Departement of Hematology, Centre Hospitalier Lyon Sud, HCL, Pierre Bénite, France

⁴Hématologie Adulte, Saint-Louis Hospital, APHP, Paris, France

⁵Departement of Hematology, CHU Rennes, Rennes, France

⁶Department of Hematology, CHU, Nantes, France

⁷Hematology, Medical University Hospital, Angers, France

⁸Department of Hematology, Institut Paoli Calmettes, Marseille, France

⁹Department of Hematology, Hôpitaux de Brabois, Vandoeuvre Lès Nancy, France

- ¹⁰Department of Hematology, CLCC H Becquerel, Rouen, France
¹¹Department of Hematology, CHU, Amiens, France
¹²Department of Hematology, Bern University Hospital, Bern, Switzerland
¹³Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
¹⁴Department of Hematology, Hôpital André Mignot, Versailles, France
¹⁵Departement of Hematology, Hôpital Saint Antoine, AP-HP, Paris, France
¹⁶Hematology, CHU Grenoble Alpes, Grenoble, France
¹⁷GRAALL Coordination, Lyon-Sud University Hospital, Pierre-Bénite, France
¹⁸Departement of Immunology, CHU, Nantes, France
¹⁹Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, APHP, Paris, France
²⁰Laboratory of Hematology, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
²¹Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, AP-HP, Paris, France
²²Division of Hematology, Geneva University Hospitals, Geneva, Switzerland
²³Departement of Hematologie, CHU, Angers, France
²⁴Departement of Hematology, Hôpital Saint-Louis, AP-HP, Paris, France

246 Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Myeloma: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma: Therapy, excluding Transplantation: Clinical Studies, Minimal Residual Disease, and Biomarkers

Hervé Avet-Loiseau^{1*}, Tineke Casneuf^{2*}, Christopher Chiu, PhD^{3*}, Jacob P. Laubach, MD⁴, Je-Jung Lee⁵, Philippe Moreau^{6*}, Torben Plesner, Professor⁷, Hareth Nahi^{8*}, Nushmia Z Khokhar^{9*}, Ming Qi^{10*}, Jordan Schecter^{11*}, Victoria Carlton, Ph.D.^{12*}, Xiang Qin^{9*}, Kevin Liu^{11*}, Kaida Wu, MD, PhD¹³, Sen H. Zhuang, M.D., Ph.D.¹⁴, Tahamtan Ahmadi, MD^{9*}, A. Kate Sasser, PhD^{9*} and Jesús F. San-Miguel¹⁵

¹Centre Hospitalier Universitaire Rangueil, Unité de Genomique du Myelome, Toulouse, France

²Oncology Heme Translational Research Group, Janssen Research & Development, Beerse, Belgium

³Oncology Heme Translational Research Group, Janssen Research & Development, LLC, Spring House, PA

⁴Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

⁵Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea, The Republic of

⁶Department of Hematology, Nantes University Hospital, Nantes, France

⁷Department of Hematology, Vejle Hospital and University of Southern Denmark, Vejle, Denmark

⁸Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden

⁹Janssen Research & Development, LLC, Spring House, PA

¹⁰Janssen Research & Development, Spring House, PA

¹¹Janssen Research & Development, LLC, Raritan, NJ

¹²Adaptive Biotechnologies Corp, South San Francisco, CA

¹³Janssen Oncology, Springhouse, PA

¹⁴Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ

¹⁵Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain

Posters

674 Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Clinical Autologous Transplantation: Results

Program: Oral and Poster Abstracts

Type: Oral

Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I

Philippe Moreau, MD^{1*}, Cyrille Hulin, MD^{2*}, Denis Caillot^{3*}, Gerald Marit, MD^{4*}, Aurore Perrot, MD^{5*}, Laurent Garderet, MD⁶, Thierry Facon⁷, Lotfi Benboubker, MD, PhD^{8*}, Lionel Karlin, MD^{9*}, Mourad Tiab^{10*}, Bertrand Arnulf, MD^{11*}, Jean-Paul Fermand¹², Xavier Leleu¹³, Cyrille Touzeau, MD^{14*}, Murielle Roussel, MD^{15*}, Lucie Planche^{16*}, Stephane Minvielle^{17*}, Marie-Christine Bene, PharmD^{18*}, **Hervé Avet-Loiseau^{15*}**, Thomas Dejoie, PharmD^{19*} and **Michel Attal²⁰**

¹hematology department, university hospital, nantes, France

²hematology department, university hospital, bordeaux, France

³Hématologie Clinique, Dijon University Hospital, Dijon, France

⁴hematology department, university hospital, Bordeaux, France

⁵hematology department, university hospital, Vandoeuvre Les Nancy, France

⁶Hematology Department, CHU St Antoine, Paris, France

⁷Hematology, CHRU Lille Hôpital Claude Huriez, Lille, Lille, France

⁸CHU Tours Hopital Bretonneau, Tours, France

⁹hematology department, Hospices Civils de Lyon, PIERRE BENITE CEDEX, FRA

¹⁰University Hospital, La Roche Sur Yon, France

¹¹hematology department, Hôpital Saint Louis, Paris, France

¹²Hopital Saint-Louis, Paris, France

¹³CHU DE POITIERS, POITIERS, France

¹⁴Department of hematology, Nantes university Hospital and UMR892 INSERM, Nantes, France

¹⁵hematology department, university hospital, toulouse, France

¹⁶university hospital, nantes, France

¹⁷Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France

¹⁸Hopital Hotel Dieu, Laboratoire d'Hematologie, Nantes, France

¹⁹Biochemistry Laboratory, Centre Hospitalier Universitaire-Nantes, Nantes, France

²⁰Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

1636 Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I

Christian Récher, MD-Ph.D.^{1,2}, Sarah Bertoli, M.D; Ph.D^{1*}, Muriel Picard, M.D^{3*}, Emilie Bérard, M.D; Ph.D^{4,5*}, Clément Larrue, PhD^{2*}, Suzanne Tavitian, M.D^{1*}, Francois Vergez, DVM, Ph.D^{6*}, Edwige Yon^{7*}, Jean Ruiz, M.D^{8*}, Eric Delabesse, PharmD, PhD^{9,10*}, Isabelle Luquet, M.D^{6*}, Laetitia Linares, PhD^{11*}, Martin Carroll, MD¹², Audrey Sarry^{13*}, **Françoise Huguët, M.D^{13*}** and **Jean-Emmanuel Sarry, PhD^{2*}**

¹Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²Centre de Recherches en Cancérologie de Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

³Service de Réanimation, CHU de Toulouse, Toulouse, France

⁴Service d'Epidémiologie,, CHU de Toulouse, Toulouse, France

⁵UMR 1027, INSERM-Université de Toulouse III, Toulouse, France

⁶Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

⁷Service d'Epidémiologie, CHU de Toulouse, Toulouse, France

⁸Service de Réanimation médicale, CHU de Toulouse, Toulouse, France

⁹Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France

¹⁰Laboratory of Hematology, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

¹¹Institut de Recherche en Cancérologie de Montpellier, INSERM, U1194, Montpellier, France

¹²Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

¹³Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

3736 Interest in Initiating Corticosteroids By Intravenous Methylprednisolone at Standard Dose in Newly Diagnosed Immune Thrombocytopenia Adults: Results of the Prospective Carmen Registry

Disorders of Platelet Number or Function

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster III

Anaïs Essilini^{1*}, Thibault Comont^{2*}, Johanne Germain, PhD^{1*}, Natacha Brun, MD^{3*}, Claire Dingremont, MD^{4*}, Brice Castel, MD^{5*}, Philippe Montané de la Roque, MD^{6*}, Serge Madaule, MD^{7*}, Laurent Sailler, MD, PhD^{8*}, Laurent Prudhomme, MD^{9*}, Sophie Arista, MD^{10*}, Laurent Balardy, MD^{11*}, Francis Gaches, MD^{12*}, **Benjamin Hebraud^{13*}**, **Cecile Borel, MD^{14,15*}**, Stéphane Sire, MD^{16*}, Miguel Carreiro, MD^{17*}, Guillaume Martin-Blondel, MD, PhD^{11*}, Laurent Alric, MD, PhD^{11*}, Patrick Giraud, MD^{18*}, Maryse Lapeyre-Mestre, MD, PhD^{19*}, **Odile Beyne-Rauzy, MD, PhD^{20*}**, **Daniel Adoue, MD, PhD^{21*}** and **Guillaume Moulis, MD, PhD^{22*}**

¹UMR 1027 INSERM-University of Toulouse, Toulouse, France

²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France

³Rodez Hospital, Rodez, France

⁴Tarbes Hospital, Tarbes, France

⁵Lourdes Hospital, Lourdes, France

⁶Pamiers Hospital, Pamiers, France

⁷Albi Hospital, Albi, France

⁸Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-University of Toulouse, Toulouse, France

⁹Castres hospital, Castres, France

¹⁰Auch hospital, Auch, France

¹¹Toulouse University Hospital, Toulouse, France

¹²Ducuing hospital, Toulouse, France

¹³Hématologie, CHU Toulouse, Toulouse, France

¹⁴Service d'Hématologie, Institut Universitaire du Cancer de Toulouse - CHU de Toulouse, Toulouse, France

¹⁵IUCT-Oncopole, Toulouse, France

¹⁶Cahors Hospital, Cahors, France

¹⁷Montauban Hospital, Montauban, France

¹⁸Pont de Chaume hospital, Montauban, France

¹⁹Service de Pharmacologie Médicale et Clinique, INSERM U 1027, Toulouse, France

²⁰Service de médecine Interne, CHU Purpan, Toulouse, France

²¹Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²²Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-, Toulouse, France

Introduction.

3996 Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014

Acute Myeloid Leukemia: Clinical Studies

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Sarah Bertoli, M.D; Ph.D^{1*}, Emilie Bérard, M.D; Ph.D^{2,3*}, Suzanne Tavitian, M.D^{1*}, Anne Huynh, MD^{4*}, Cecile Borel, MD^{5*}, Sarah Guenounou^{1*}, Isabelle Luquet, M.D^{6*}, Eric Delabesse, PharmD, PhD^{7*}, Audrey Sarry^{4*}, **Guy Laurent, M.D; Ph.D¹**, Michel Attal⁸, Françoise Huguet, M.D^{4*} and **Christian Récher, MD-Ph.D.^{1,9}**

¹Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²Service d'Epidémiologie,, CHU de Toulouse, Toulouse, France

³UMR 1027, INSERM-Université de Toulouse III, Toulouse, France

⁴Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

⁵Service d'Hématologie, Institut Universitaire du Cancer de Toulouse - CHU de Toulouse, Toulouse, France

⁶Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

⁷Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France

⁸Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

⁹Centre de Recherches en Cancérologie de Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

1367 Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a Prospective Multicenter Cohort Study of 218 Patients

Disorders of Platelet Number or Function

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster I

Guillaume Moulis, MD, PhD^{1*}, Thibault Comont^{2*}, Johanne Germain, PhD^{3*}, Anaïs Essilini^{3*}, Natacha Brun, MD^{4*}, Claire Dingremont, MD^{5*}, Brice Castel, MD^{6*}, Philippe Montané de la Roque, MD^{7*}, Serge Madaule, MD^{8*}, Laurent Sailler, MD, PhD^{9*}, Laurent Prudhomme, MD^{10*}, Sophie Arista, MD^{11*}, Laurent Balardy, MD^{12*}, Francis Gaches, MD^{13*}, Benjamin Hebraud^{14*}, Cecile Borel, MD^{15*}, Stéphane Sire, MD^{16*}, Miguel Carreiro, MD^{17*}, Guillaume Martin-Blondel, MD, PhD^{12*}, Laurent Alric, MD, PhD^{12*}, Patrick Giraud, MD^{18*}, Maryse Lapeyre-Mestre, MD, PhD^{19*}, **Odile Beyne-Rauzy, MD, PhD^{20*}** and **Daniel Adoue, MD, PhD^{21*}**

¹Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-, Toulouse, France

²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France

³UMR 1027 INSERM-University of Toulouse, Toulouse, France

⁴Rodez hospital, Rodez, France

⁵Tarbes Hospital, Tarbes, France

⁶Lourdes Hospital, Lourdes, France

⁷Pamiers Hospital, Pamiers, France

⁸Albi Hospital, Albi, France

⁹Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-University of Toulouse, Toulouse, France

¹⁰Castres hospital, Castres, France

¹¹Auch hospital, Auch, France

¹²Toulouse University Hospital, Toulouse, France

¹³Ducuing hospital, Toulouse, France

¹⁴Hématologie, CHU Toulouse, Toulouse, France

¹⁵Service d'Hématologie, Institut Universitaire du Cancer de Toulouse - CHU de Toulouse, Toulouse, France

¹⁶Cahors Hospital, Cahors, France

¹⁷Montauban Hospital, Montauban, France

¹⁸Pont de Chaume hospital, Montauban, France

¹⁹Service de Pharmacologie Médicale et Clinique, INSERM U 1027, Toulouse, France

²⁰Service de médecine Interne, CHU Purpan, Toulouse, France

²¹Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

3991 Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?

Acute Myeloid Leukemia: Clinical Studies

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Sarah Bertoli, M.D; Ph.D^{1*}, Noemie Gadaud^{2*}, Suzanne Tavitian, M.D^{1*}, **Audrey Sarry^{3*}**, **Emilie Bérard, M.D; Ph.D^{4,5*}**, **Françoise Huguet, MD^{1*}** and **Christian Recher, MD, PhD^{1,6}**

¹Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

³Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

France

⁴Service d'Epidémiologie,, CHU de Toulouse, Toulouse, France

⁵UMR 1027, INSERM-Université de Toulouse III, Toulouse, France

⁶Centre de Recherches en Cancérologie de Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

4764 Validation of an Algorithm Identifying Incident Primary Immune Thrombocytopenia in the French National Health Insurance Database

Outcomes Research—Non-Malignant Conditions

Program: Oral and Poster Abstracts

Session: 903. Outcomes Research—Non-Malignant Conditions: Poster III

Salim Mezaache^{1*}, H el ene Derumeaux, MD, PhD^{2*}, Pierre Ferraro, MD^{3*}, Pascal Capdebon, MD^{4*}, Jean-Christophe Steinbach, MD^{5*}, Xavier Aballe, MD^{6*}, Deborah Palas, MD^{7*}, Nabil Saichi, MD^{8*}, Franck Burgan, MD^{9*}, Karine Desboeuf, MD^{10*}, Maryse Lapeyre-Mestre, MD, PhD^{11*}, Laurent Sailler, MD, PhD^{12*} and **Guillaume Moulis, MD, PhD^{13,14*}**

¹UMR 1027 INSERM-University of Toulouse, Toulouse, France

²Department of Medical Information, Toulouse University Hospital, Toulouse, France

³Department of Medical Information, Auch Hospital, Auch, France

⁴Department of Medical Information, Tarbes Hospital, Tarbes, France

⁵Department of Medical Information, Castres Hospital, Castres, France

⁶Department of Medical Information, Montauban Hospital, Montauban, France

⁷Department of Medical Information, Albi Hospital, Albi, France

⁸Department of Medical Information, Foix-Pamiers Hospital, Pamiers, France

⁹Department of Medical Information, Pont-de-Chaume Hospital, Montauban, France

¹⁰Department of Medical Information, Lavaur Hospital, Lavaur, France

¹¹Service de Pharmacologie M edicale et Clinique, INSERM U 1027, Toulouse, France

¹²Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-University of Toulouse, Toulouse, France

¹³Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-, Toulouse, France

¹⁴CIC 1436, Toulouse University Hospital, Toulouse, France

3987 Platelet Transfusion Refractoriness Following Induction Chemotherapy in Acute Myeloid Leukemia

Acute Myeloid Leukemia: Clinical Studies

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III

Thibault Comont^{1*}, Suzanne Tavitian, M.D.^{2*}, Laurent Bardiaux^{3*}, Marylise Fort^{4*}, Benedicte DebioI^{3*}, Daniele Morere^{3*}, Fran oise Huguet, MD^{2*}, Christian R echer, MD-Ph.D.^{2,5} and Sarah Bertoli, M.D; Ph.D.^{2*}

¹Service de M edicine Interne, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²Service d'H ematologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

³Etablissement Fran ais du Sang, Toulouse, France

⁴Immunology, Toulouse University Hospital, toulouse, France

⁵Centre de Recherches en Canc erologie de Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

2552 Effect of Pregnancy in Women with a History of Primary Immune Thrombocytopenia Considered As Cured

Disorders of Platelet Number or Function

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster II

Thibault Comont^{1*}, Guillaume Moulis, MD, PhD^{2,3*}, Karen Delavigne, MD^{1*}, Pierre Cougoul, MD^{1*}, Olivier Parant, MD, PhD^{4*}, Beatrice Guyard Boileau, MD^{4*}, Christian R echer, MD-Ph.D.⁵, Daniel Adoue, MD, PhD^{1*} and Odile Beyne Rauzy, MD, PhD^{1*}

¹Service de M edicine Interne, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-, Toulouse, France

³CIC 1436, Toulouse University Hospital, Toulouse, France

⁴Department of Obstetrics and Gynecology, Paule de Viguier Hospital - CHU de Toulouse, Toulouse, France

⁵Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

1718 Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and

Prognosis: Poster I

Sarah Bertoli, M.D; Ph.D^{1*}, Suzanne Tavitian, M.D^{1*}, Eric Delabesse, PharmD, PhD^{2,3*}, Audrey Sarry^{4*}, Françoise Huguet, M.D^{4*} and Christian Récher, MD-Ph.D.^{1,5}

¹Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France

³Laboratory of Hematology, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

⁴Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

⁵Centre de Recherches en Cancérologie de Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

3576 Impact of Non Professional Physicians' Characteristics on Medical Decision Making in Older Patients with Acute Myeloid Leukemia

Health Services Research—Malignant Conditions

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Conditions: Poster II

Pierre Bories, MD^{1,2*}, Sébastien Lamy, PhD^{3,4*}, Célestine Simand^{5*}, Sarah Bertoli, M.D; Ph.D^{1*}, Sandra Malak, MD^{6*}, Luc Mathieu Fornecker, MD, PhD^{5*}, Stephane Moreau, MD^{7*}, Christian Recher, MD, PhD^{1,8} and Antoine Nebout, PhD^{9*}

¹Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

²Réseau régional de cancérologie ONCOMIP, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

³Department of clinical pharmacology, Toulouse university hospital, Toulouse, France

⁴Laboratory of Epidemiology and Analyses in public health (LEASP) - UMR 1027 Inserm, Toulouse III University, Toulouse, France

⁵Haematology, University Hospital, Strasbourg, France

⁶Hopital Rene Huguenin-Institut Curie, Saint Cloud, FRA

⁷Haematology, University Hospital, Limoges, France

⁸Centre de Recherches en Cancérologie de Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

⁹UR 1303 ALISS,, INRA University Paris-Saclay, Ivry-sur-Seine, France

2138 Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Myeloma: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Eileen Mary Boyle, MD, MSc^{1*}, Marie-Odile Petillon, MD^{1*}, Charles Herbaux, MD^{1*}, Johanna Mimouni^{2*}, Xavier Leleu³, Lionel Karlin, MD^{4*}, Chantal Doyen, MD⁵, Marc Wetterwald, MD, PhD^{6*}, Muriel Roussel, MD^{7*}, Cyrille Hulin^{8*}, Bruno Royer, MD^{9*}, Margaret Macro^{10*}, Philippe Moreau^{11*}, Karel Fostier, MD^{12*}, Mamoun Dib^{13*}, Sabine Brechignac, MD^{14*}, Caroline Bureau^{15*}, Gerald Marit, MD^{16*}, Adrian Tempescul, MD^{17*}, Marie Lorraine Chretien^{18*}, Charles Zarnitsky^{19*}, Cecile Fohrer, MD^{20*}, Aurore Perrot, MD^{21*}, Lotfi Benboubker, MD, PhD^{22*}, Laurent Voillat^{23*}, Jean Valere Malfuson^{24*}, Clara Mariette^{25*}, Mourad Tiab^{26*}, Sophie Rigaudeau^{27*}, Arnaud Jaccard, MD, PhD^{28*}, Anne-Marie Stoppa²⁹, Laure Vincent^{30*}, Jean Claude Eisenmann, MD^{31*}, Laurent Frenzel^{32*}, Bertrand Arnulf, MD^{33*}, Mohamad Mohty, MD, PhD³⁴, Philippe Rodon, MD³⁵, Brigitte Kolb^{36*}, Olivier Decaux,

MD, PhD^{37*}, Pascal Godmer^{38*}, David Beauvais^{1*}, Benjamin Carpentier^{1*}, Sarah Bonnet, MD^{1*}, Thomas Longval^{1*}, Mathieu Dewevre^{1*}, Hervé Avet-Loiseau^{39*}, Michel Attal⁴⁰, Susanna Schraen, PharmD^{41*} and Thierry Facon⁴²

¹Service des maladies du sang, Lille University Hospital, Lille, France

²Departement de recherche clinique, Lille University Hospital, Lille, France

³CHU DE POITIERS, POITIERS, France

⁴hematology department, Hospices Civils de Lyon, PIERRE BENITE CEDEX, FRA

⁵Department of Hematology, CHU Dinant Godinne Ucl, Yvoir, Belgium

⁶CHD Dunkerque, Dunkerque, France

⁷Institut Universitaire du Cancer and University Hospital, Hematology department, Toulouse, France

⁸Bordeaux Hospital University Center (CHU), Bordeaux, France

⁹Department of Hematology, University Hospital, Amiens, France

¹⁰Hopital Cote De Nacre, Caen Cedex 9, FRA

¹¹Department of Hematology, Nantes University Hospital, Nantes, France

¹²Uz Brussel, Brussel, BEL

¹³Hématologie - CHU - Hôpital du Bocage, Angers, France

¹⁴Hopital Avicenne, bobigny, France

¹⁵Polyclinique Bordeaux Nord Aquitaine, Bordeaux Cedex, FRA

¹⁶hematology department, university hospital, Bordeaux, France

¹⁷Hematology Department, CHU Brest, Brest, France

¹⁸Hématologie Clinique CHU DIJON, Dijon, France

¹⁹Hopital J Monod, Brest, France

²⁰HEMATOLOGY, CHU, Strasbourg, FRA

²¹hematology department, university hospital, Vandoeuvre Les Nancy, France

²²Hôpital Bretonneau Service Hématologie et Thérapies Cellulaires, Centre Régional de Cancérologie Henry Kaplan CHRU de Tours, Tours, France

²³Centre Hospitalier William Morey, Chalons-sur-Saone, France

²⁴Hôpital d'instruction des armées Percy, Paris Cedex 10, FRA

²⁵Hematology, Grenoble University Hospital, Grenoble, France

²⁶University Hospital, La Roche Sur Yon, France

²⁷Service Hematologie, CHU Andre Mignot, Versailles, France

²⁸Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts, CHU Limoges, Limoges, France

²⁹Institut Paoli Calmettes, Marseille, France

³⁰CHU, Montpellier, FRA

³¹Hematology Department, CH Mulhouse, Mulhouse, France

³²Hopital Necker, Paris, FRA

³³hematology department, Hôpital Saint Louis, Paris, France

³⁴Department of Haematology, EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France

³⁵Centre Hospitalier, Perigueux, France

³⁶Hopital Robert Debre, Reims Cedex, France

³⁷Internal Medicine, University Hospital CHU Rennes, Rennes, France

³⁸Department of Hematology, Hospital, Bretagne atlantique, France

³⁹IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

⁴⁰Institut Universitaire du Cancer-Oncopole, Toulouse, France

⁴¹Department of biochemistry, Lille University Hospital, Lille, France

⁴²Service des Maladies du Sang, Hopital Claude Huriez, Lille, France

1743 Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study

Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis Program: Oral and Poster Abstracts

Session: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Laura Clement^{1*}, Stefan Suciu, PhD², Isabelle Luquet, M.D.^{3*}, Alina Ferster, MD, PhD⁴, Karima Yakouben, MD^{5*}, Anne Uytterbroeck^{6*}, Catherine Paillard, MD PhD^{7*}, Nicolas Sirvent^{8*}, Vitor Costa^{9*}, Barbara De Moerloose,

MD^{10*}, Françoise Mazingue¹¹, Emmanuel Plouvier, MD^{12*}, Martine Munzer^{13*}, Maryline Poirée^{14*}, Odile Minckes, MD^{15*}, Frédéric Millot, MD^{16*}, Dominique Plantaz^{17*}, Caroline Piette^{18*}, Frank Speleman, Prof^{19*}, Hélène Cavé^{20*}, Jutte VanderWerff-tenBossch^{21*}, Pierre Simon Rohrlisch, MD PhD^{22*}, Yves Bertrand^{23*}, Yves Benoit²⁴ and Geneviève Plat^{25*}

¹CHU Toulouse, Toulouse, France

²EORTC Headquarters, Brussels, Belgium

³Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

⁴Dept. of Hémato-oncologie pédiatrique, Children's University Hospital Reine Fabiola, Brussels, Belgium

⁵Robert Debre Hospital, AP-HP, Paris, France

⁶U.Z. gasthuisberg, Leuven, Belgium

⁷Pediatric Hematology, CHU Strasbourg, Strasbourg, France

⁸Pediatric Hematology and oncology department, CHU Montpellier, Montpellier, France

⁹Instituto Portugues de Oncologia - Centro do Porto, Porto, Portugal

¹⁰Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

¹¹hematology, CHRU Lille, Lille, France

¹²pediatric hematology, CHRU Besançon, Besançon, France

¹³CHU Reims, Reims, France

¹⁴CHU Nice, Nice, France

¹⁵Pediatric Oncology Hematology Department, CHU Caen, Caen, France

¹⁶University Hospital, Poitiers, FRA

¹⁷Department of Pediatric Hematology-Oncology,, CHU Grenoble, Grenoble, France

¹⁸University Department of Pediatric Oncology, CHR Citadelle, Liège, Belgium

¹⁹Center for Medical Genetics, Ghent University, Ghent, Belgium

²⁰Hôpital Robert Debré, AP-HP, Paris, France

²¹U.Z. Gasthuisberg, Leuven, Belgium

²²Hematology-Pediatrics, Besançon, FRA

²³CHU Lyon, Lyon, France

²⁴Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, University Hospital Ghent, Ghent, Belgium

²⁵Department of Hematology, CHU Toulouse, Toulouse, France

2128 IFM2012-03

Myeloma: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Xavier Leleu¹, Guillemette Fouquet^{2*}, Lionel Karlin, MD^{3*}, Brigitte Kolb^{4*}, Mourad Tiab^{5*}, Carla Araujo^{6*}, Nathalie Meuleman, MD, PhD⁷, Jv Malfuson⁸, Pascal Bourquard, MD^{9*}, Pascal Lenain^{10*}, Murielle Roussel, MD^{11*}, Arnaud Jaccard, MD, PhD^{12*}, Marie-Odile Petillon, MD^{13*}, Karim Belhadj-Merzoug^{14*}, Gerard Lepeu^{15*}, Marie-Lorraine Chretien^{16*}, Jean Fontan^{17*}, Philippe Rodon, MD¹⁸, Anna Schmitt, MD^{19*}, Fritz Offner^{20*}, Laurent Voillat^{21*}, Sophie Cereja^{22*}, Frederique Kuhnowski^{23*}, Sophie Rigaudeau^{24*}, Olivier Decaux, MD, PhD^{25*}, Catherine Humbrecht-Kraut^{26*}, Jamile Frayfer, MD^{27*}, Olivier Fitoussi, MD^{28*}, Damien Roos Weil^{29*}, Jean Claude Eisenmann, MD^{30*}, Veronique Dorvaux^{31*}, Eric G. Voog, MD³², Cyrille Hulin^{33*}, **Michel Attal**³⁴, Philippe Moreau^{35*} and Thierry Facon³⁶

¹ONCOLOGIE HEMATOLOGIQUE ET THERAPIE CELLULAIRE, CHU DE POITIERS, POITIERS, France

²Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France

³Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France

⁴Hopital Robert Debre, Reims Cedex, France

⁵University Hospital, La Roche Sur Yon, France

⁶Centre Hospitalier de la côte basque, Bayonne, France

⁷Hematology, Institut Jules Bordet, ULB, Brussels, Belgium

⁸Dept. of Hematology, Hopital Percy, Clamart, France

⁹Hopital Caremeau, Nimes, France

¹⁰Centre Henri Becquerel, Rouen, France

- ¹¹HEMATOLOGY, IUCT ONCOPOLE, Toulouse, France
- ¹²Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts, CHU Limoges, Limoges, France
- ¹³Service des maladies du sang, Lille University Hospital, Lille, France
- ¹⁴Service Hematologie, CHU Henri Mondor, Creteil, France
- ¹⁵Service Hematologie, Centre Hospitalier H. Duffaut, Avignon, France
- ¹⁶Hospital Bocage, Dijon, France
- ¹⁷Service Hematologie, CHU Besancon, Besancon, France
- ¹⁸Centre Hospitalier, Perigueux, France
- ¹⁹Hematology Department, Institut Bergonie, Bordeaux, France
- ²⁰Ghent University Hospital, Ghent, Belgium
- ²¹Department of Hematology, Hospital, Chalon sur saone, France
- ²²Service Hematologie, CH Francilien, Corbeil-Essones, France
- ²³Service Hematologie, Institut Curie, Paris, France
- ²⁴Service Hematologie, CHU Andre Mignot, Versailles, France
- ²⁵Internal Medicine, University Hospital CHU Rennes, Rennes, France
- ²⁶Service Onco-Hematologie, CH Louis Pasteur, Colmar, France
- ²⁷Hématologie, Meaux Hospital, Meaux, France
- ²⁸Polyclinique Bordeaux Nord-Aquitaine, Bordeaux, France
- ²⁹Service Hematologie, AP-HP Groupe Hospitalier Pitie-Salpetriere, Paris, France
- ³⁰Hematology Department, CH Mulhouse, Mulhouse, France
- ³¹Medecine Interne, Hopital Notre Dame de Bon Secours, Metz-Thionville, France
- ³²Hematology Department, Le Mans, Centre Jean Bernard, Le Mans, France
- ³³Bordeaux Hospital University Center (CHU), Bordeaux, France
- ³⁴Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
- ³⁵Hematology, University Hospital Hôtel Dieu, Nantes, France
- ³⁶Hematology, CHRU Lille Hôpital Claude Huriez, Lille, France

3128 Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Myeloproliferative Syndromes: Clinical

Program: Oral and Poster Abstracts

Session: 634. Myeloproliferative Syndromes: Clinical: Poster II

Brigitte Dupriez, MD¹, Sylvie Chevret, MD, PhD^{2*}, Jean-Christophe Ianotto, MD^{3*}, Françoise Boyer, MD^{4*}, Pascale Cony-Makhoul, MD^{5*}, Gabriel Etienne, MD, PhD^{6*}, Mathieu Wemeau, MD^{7*}, Jérôme Rey^{8*}, Laurent Knoops, MD, PhD^{9*}, Jean-Loup Demory, MD¹⁰, Eric Lippert, PhD^{3*}, François Girodon, MD, PhD¹¹, Laurence Legros, MD, PhD^{12*}, Anne Vekhoff, MD^{13*}, Stéphane Courby, MD^{14*}, Fabienne Vacheret, MD^{15*}, Nathalie Cambier, MD^{16*}, Stéphane Giraudier, MD, PhD^{17*}, **Suzanne Tavitian, M.D^{18*}**, Kamel Laribi, MD^{19*}, Sandra Malak^{20*}, Dana Ranta, MD^{21*}, Fiorenza Barraco, MD^{22*}, Isabelle Plantier, MD^{23*}, Sophie Dupire^{24*}, Marc Simon, MD^{25*}, Selim Corm, MD^{26*}, Ahmad AL Jijakli, MD^{27*}, Philippe Rodon, MD²⁸, Lise Willems, MD, PhD^{29*}, Bohrane Slama, MD^{30*}, Ronan Le Calloch, MD^{31*}, Pierre Morel, MD^{32*}, Valerie Ugo, MD, PhD^{33*} and Jean-Jacques Kiladjian, MD, PhD³⁴

¹Service Hematologie Clinique, Centre hospitalier de Lens, Lens, France

²Biostatistics department, Hôpital Saint-Louis, Paris, France

³Centre Hospitalier Universitaire, Brest, France

⁴Centre Hospitalier Universitaire, Angers, France

⁵Centre Hospitalier Annecy-Genevois, Pringy, France

⁶Hematology Department, Institut Bergonie, Bordeaux, France

⁷CH, Arras, France

⁸Hematology Department, Institut Paoli Calmettes, Marseille, France

⁹Cliniques Universitaires Saint-Luc and de Duve Institute, Université catholique de Louvain, Brussels, Belgium

¹⁰Hôpitaux de l'Université Catholique de Lille, Lille, France

¹¹Hospital University Center (CHU), Dijon, France

¹²Hematology department, Hopital Archet 1, CHU Nice, Nice, France

¹³Hematology and Cellular Therapy, Saint Antoine Hospital, Paris, France

¹⁴Hematology department, CHU Grenoble, Grenoble, France

- ¹⁵CH, Perpignan, France
- ¹⁶CHRU, Lille, France
- ¹⁷Hôpital Henri-Mondor, Créteil, France
- ¹⁸Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France
- ¹⁹Centre Hospitalier, Le Mans, France
- ²⁰CHU Curie, Paris, France
- ²¹Centre Hospitalier Universitaire, Nancy, Nancy, France
- ²²Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France
- ²³CH, Roubaix, France
- ²⁴CH, Bourg en Bresse, France
- ²⁵Centre Hospitalier, Valenciennes, France
- ²⁶Médipole de Savoie, Challes Les Eaux, France
- ²⁷CH Argenteuil, Argenteuil, France
- ²⁸Centre Hospitalier, Perigueux, France
- ²⁹Cochin Hospital, University Paris 5, Paris, France
- ³⁰CH, Avignon, France
- ³¹CH, Quimper, France
- ³²Department of Hematology, University Hospital, Amiens, France
- ³³Laboratoire Hematologie, CHU Angers, Angers, France
- ³⁴Hôpital Saint-Louis and Paris Diderot University, Paris, France

241 Final Analysis of Overall Survival from the First Trial

Myeloma: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma: Therapy, excluding Transplantation: Clinical Studies, Minimal Residual Disease, and Biomarkers

Thierry Facon¹, Meletios Dimopoulos², Angela Dispenzieri³, John V. Catalano⁴, Andrew Belch⁵, Michele Cavo, MD^{6*}, Antonello Pinto^{7*}, Katja Weisel^{8*}, Heinz Ludwig⁹, Nizar J. Bahlis, MD^{10,11}, Anne Banos^{12*}, Mourad Tiab^{13*}, Michel Delforge¹⁴, Jamie D. Cavenagh¹⁵, Catarina Geraldes^{16*}, Je-Jung Lee¹⁷, Christine Chen^{18*}, Albert Oriol^{19*}, Javier De La Rubia^{20*}, Darrell White²¹, Daniel Binder²², Jin Lu²³, Kenneth C. Anderson²⁴, Philippe Moreau^{25*}, **Michel Attal**²⁶, Jean-Paul Fermand²⁷, **Hervé Avet-Loiseau**^{28*}, Annette Ervin-Haynes²⁹, Guang Chen^{29*}, Vanessa Houck^{29*}, Cyrille Hulin^{30*} and Lofti Benboubker^{31*}

¹Service des Maladies du Sang, Hopital Claude Huriez, Lille, France

²National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

³Mayo Clinic, Rochester, MN

⁴Frankston Haematology and Oncology Center, Frankston, Australia

⁵Cross Cancer Institute, Edmonton, AB, Canada

⁶Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

⁷Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione Pascale, IRCCS, Napoli, Italy

⁸University of Tuebingen, Tuebingen, Germany

⁹Wilhelminen Cancer Research Institute, Department of Medicine, Center of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria

¹⁰University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada

¹¹University of Calgary, Calgary, AB, Canada

¹²Centre Hospitalier de la Cote basque, Bayonne, France

¹³University Hospital, La Roche Sur Yon, France

¹⁴Department of Hematology, UZ Leuven, Leuven, Belgium

¹⁵Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom

¹⁶Hospitals da Universidade de Coimbra, Coimbra, Portugal

¹⁷Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea, The Republic of

¹⁸Princess Margaret Cancer Centre, Toronto, ON, Canada

- ¹⁹Hospital Germans Trias i Pujol, Barcelona, Spain
²⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
²¹QEII Health Sciences Center, Dalhousie University, Halifax, NS, Canada
²²Kantonsspital Winterthur, Winterthur, CHE
²³Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China
²⁴Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
²⁵University of Nantes, Nantes, France
²⁶Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
²⁷Hopital Saint-Louis, Paris, France
²⁸Unite de Genomique du Myelome, CHU Ranguel, Toulouse, France
²⁹Celgene Corporation, Summit, NJ
³⁰Bordeaux Hospital University Center (CHU), Bordeaux, France
³¹CHU Tours Hopital Bretonneau, Tours, France

3569 Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM

Health Services Research—Malignant Conditions

Program: Oral and Poster Abstracts

Session: 902. Health Services Research—Malignant Conditions: Poster II

Zoe van de Wyngaert^{1*}, Nabih Azar, MD^{2*}, Pascal Lenain^{3*}, Margaret Macro^{4*}, Jean-Henri Bourhis, MD, PhD⁵, Laurent Garderet, MD⁶, Arnaud Jaccard, MD, PhD^{7*}, Lionel Karlin, MD^{8*}, Christine Giraud^{9*}, Stéphanie Guidez, MD^{10*}, Benjamin Hebraud^{11*}, Muriel Roussel, MD^{12*}, Gerald Marit, MD^{13*}, Cyrille Hulin, MD^{14*}, Eric Deconinck, MD, PhD¹⁵, Michel Attal¹⁶, Philippe Moreau^{17*}, Denis Caillot^{18*}, Samuel Limat, PhD^{19*}, Xavier Leleu²⁰ and Marie-Lorraine Chretien^{21*}

¹Service des Maladies du sang, hopital claud hurriez, CHRU lille, Lille, France

²Service d'Hématologie Clinique, Hôpital de la Pitié-Sâlpétrière, PARIS CEDEX 13, France

³Centre Henri Becquerel, Rouen, France

⁴Haematology Department, Caen University Hospital, Caen, France

⁵Division of Hematology, Institut Gustave Roussy, Villejuif, France

⁶Hematology Department, CHU St Antoine, Paris, France

⁷Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts, CHU Limoges, Limoges, France

⁸hematology department, Hospices Civils de Lyon, PIERRE BENITE CEDEX, FRA

⁹CHU de POITIERS, Poitiers, FRA

¹⁰Oncologie hématologique et thérapie cellulaire, CHU Poitiers, Poitiers, France

¹¹CHU Toulouse, TOULOUSE, FRA

¹²Institut Universitaire du Cancer and University Hospital, Hematology department, Toulouse, France

¹³hematology department, university hospital, Bordeaux, France

¹⁴hematology department, university hospital, bordeaux, France

¹⁵Hematology, INSERM UMR1098 - CHU Jean Minjoz, Besancon, France

¹⁶Institut Universitaire du Cancer-Oncopole, Toulouse, France

¹⁷Department of Hematology, Nantes University Hospital, Nantes, France

¹⁸Hématologie Clinique, Dijon University Hospital, Dijon, France

¹⁹Pharmacy, CHRU Besancon, Université de Bourgogne Franche -comté, Besançon, France

²⁰ONCOLOGIE HEMATOLOGIQUE ET THERAPIE CELLULAIRE, CHU DE POITIERS, POITIERS, France

²¹Hospital Bocage, Dijon, France

3476 Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry

Clinical Allogeneic Transplantation: Results

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Franck-Emmanuel Nicolini, MD, PhD^{1,2}, Valerie Coiteux, MD^{2,3*}, Gerard Socie, MD, PhD⁴, Didier Blaise, MD, PhD⁵, Eric Deconinck, MD, PhD⁶, Patrice Chevallier, MD, PhD^{7*}, Pierre Simon Rohrllich^{8*}, Stephanie Nguyen, MD,

PhD^{9*}, Thierry Lamy, MD PhD¹⁰, Jean-Henri Bourhis, MD, PhD¹¹, Marie-Thérèse Rubio, MD, PhD^{12*}, Felipe Suarez, MD, PhD¹³, Jerome Cornillon, MD^{14*}, Gandhi Damaj, MD¹⁵, Natacha Maillard, MD^{16*}, Noeli Milpied, MD PhD¹⁷, Patrice Ceballos, MD^{18*}, Mohamad Mohty, MD, PhD¹⁹, Claude-Eric Bulabois, MD^{20*}, Bruno Lioure, MD^{21*}, Gerard Michel, MD^{22*}, Norbert Ifrah²³, Yves Beguin, MD, PhD²⁴, Anne Huynh, MD^{25*}, Nathalie Contentin, MD^{26*}, Jacques-Olivier Bay, MD, PhD²⁷, Yves Bertrand, MD, PhD^{28*}, Yves Perel, MD^{29*}, Jean-Hugues Dalle, MD, PhD, Prof.³⁰, Gaelle Guillermin, MD^{31*}, Jean-Valere Malfuson, MD^{32*}, Aude Marie-Cardine, MD^{33*}, Mauricette Michallet, MD, PhD^{2,34}, Nicole Raus, Data Manager^{35*}, Marie Balsat, MD^{36*}, Helene Labussiere, MD^{34*}, Regis Peffault De Latour, MD, PhD^{4*} and Ibrahim Yakoub-Agha, MD, PhD³⁷

¹Centre Hospitalier Lyon Sud, Hématologie clinique 1G, Pierre Bénite, France

²Fi-LMC group, Pessac, France

³Hematology, CHU de Lille, Lille, France

⁴Hematology / Transplantation, Saint Louis Hospital, Paris, France

⁵Programme de Transplantation & Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

⁶Hematology, INSERM UMR1098 - CHU Jean Minjoz, Besancon, France

⁷Department of Hematology, Nantes University Hospital, Nantes, France

⁸Pediatric Oncology, CHU Nice, Nice, France

⁹Department of hematology, Pitie Salpetriere Hospital, Paris, France

¹⁰INSERM U917, CHU Pontchaillou, Rennes, France

¹¹Gustave Roussy Cancer Center, Villejuif, France

¹²Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

¹³Hôpital Universitaire Necker-Enfants Malades, Paris, France

¹⁴Department of Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France

¹⁵Hematology Department, CHU Caen, Caen, France

¹⁶Bone Marrow Transplant Unit Clinical Hematology, Hopital La Miletrie, Poitiers, France

¹⁷Service d'Hématologie et de Thérapie Cellulaire, CHU Haut-Leveque and University of Bordeaux, Bordeaux, France

¹⁸Hematology, CHU Lapeyronie, Montpellier, France

¹⁹Department of Haematology, EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France

²⁰Hematology, CHU Grenoble, Grenoble, France

²¹Hematology and Oncology, Hopital Hautepierre, Strasbourg, France

²²Hematology, CH Timone, Marseille, France

²³Hematology, Angers University Hospital, Angers, France

²⁴Hematology, University and CHU of Liege, Liege, Belgium

²⁵Institut Universitaire du Cancer, Oncopole IUCT, Toulouse, France

²⁶Hematology, Centre Henri Becquerel, Rouen, France

²⁷Hematology department, CHU Clermont Ferrand, Clermont Ferrand, France

²⁸Department of Pediatric Hematology and Oncology, University Hospital of Lyon, Lyon, France

²⁹Pediatric Hematology department, CHU Pellegrin, Bordeaux, France

³⁰Pediatric Hematology Department, Robert Debre Hospital, Paris, France

³¹Hematology and Oncology, CH Augustin Morvan, Brest, France

³²Military Hospital, Clamart, France

³³Pediatric Hematology department, Charles Nicolle Hospital, Rouen, France

³⁴Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

³⁵SFGM-TC, Lyon, France

³⁶Hématologie Clinique, Lyon-Sud Hospital, Pierre Benite, France

³⁷Hematology, Hôpital HURIEZ UAM allogreffe de CSH, CHRU, Lille, France

3696 Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group

Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III

Mauricette Michallet, MD, PhD¹, Mohamad Sobh, PharmD^{1*}, Alexandre Deloire, CRA^{1*}, Emmanuel Raffoux, MD^{2*}, Stephane de Botton^{3*}, Denis Caillot^{4*}, Oumedaly Reman, MD⁵, Stephane Girault, MD^{6*}, Celine Berthon,

MD, PhD^{7*}, **Francoise Huguet, MD^{8*}**, Stephane Lepretre^{9*}, Thibaut Leguay, MD^{10*}, Sylvie Castaigne, MD, PhD¹¹, Bruno Royer, MD^{12*}, Cecile Pautas, MD^{13*}, Jean-Valere Malfuson, MD^{14*}, Jose Fernandes, MD^{15*}, Thomas Prebet, MD^{16*}, Thorsten Braun, MD^{17*}, Lauris Gastaud, MD^{18*}, Felipe Suarez, MD, PhD¹⁹, Aline Schmidt, MD^{20*}, Remy Gressin, MD²¹, Jacques Delaunay, MD^{22*}, Caroline Bonmati, MD^{23*}, Karine Celli-Lebras, CRA^{24*}, Mohamed El-Hamri, CRA^{1*}, Herve Dombret, MD, PhD², Xavier Thomas, MD, PhD¹ and Anne Bergeron, MD, PhD^{25*}

¹Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

²Hematology Department, Saint Louis Hospital, Paris, France

³Institut Gustave Roussy, Villejuif, France

⁴Hématologie Clinique, Dijon University Hospital, Dijon, France

⁵Hematology, CHU Caen, Caen, France

⁶Hematology, Limoges university hospital, Limoges, France

⁷Hematology, CHRU de Lille, Lille, France

⁸Hématologie, Toulouse Cancer University Institute, Toulouse, France

⁹Hematology, Henri Becquerel Anti-Cancer Center, Rouen, France

¹⁰Hematology, CHU Bordeaux, Pessac, France

¹¹Hematology, Hopital Mignot, Le Chesnay, France

¹²Department of Hematology, University Hospital, Amiens, France

¹³Hematology, Henri Mondor Hospital, Creteil, France

¹⁴Hematology, Military Hospital, Clamart, France

¹⁵Hematology, Centre Hospitalier Valenciennes, Valenciennes, France

¹⁶Hematology, Institut Paoli-Calmettes, Marseille, France

¹⁷Hematology, Avicenne Hospital, APHP, Bobigny, France

¹⁸Hematology, Centre Antoine Lacassagne, Nice, France

¹⁹Hôpital Universitaire Necker-Enfants Malades, Paris, France

²⁰Hematology, CHU angers, Angers, France

²¹Hematology, CHU Grenoble, Grenoble, France

²²Hematology, Nantes University Hospital, Nantes, France

²³Hematology, CHU Nancy, Nancy, France

²⁴ALFA group, Paris, France

²⁵Pneumology, Saint Louis Hospital, Paris, France

????

3450 Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a French Multicenter Study of 386 Patients from Lysa Centers

Clinical Autologous Transplantation: Results

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster II

Sylvain Chantepie, MD^{1*}, Emmanuelle Tchernonog, MD^{2*}, Frederic Peyrade, MD^{3*}, Marie-Virginie Larcher, MD^{4*}, Momar Diouf, MD^{5*}, Luc Mathieu Fornecker, MD, PhD^{6*}, Roch Houot, MD, PhD^{7*}, Thomas Gastinne, MD^{8*}, Carole Soussain, MD, PhD⁹, Sandra Malak, MD^{10*}, Olivier Tournilhac, MD, PhD^{11*}, Caroline Delette^{12*}, Ahmad Ibrahim^{13*}, Anne-Claire Gac, MD^{1*}, Jean-Pierre Vilque, MD^{14*}, Mohamed Amine Bekadja^{15*}, Rene-Olivier Casasnovas, MD^{16*}, Remy Gressin, MD¹⁷, Arnaud Jaccard, MD, PhD^{18*}, Benjamin Carpentier^{19*}, Reda Garidi, MD^{20*}, Bachra Choufi, MD^{21*}, Stéphanie Guidez, MD^{22*}, Adrian Tempescul, MD^{23*}, Adrien Chauchet, MD^{24*}, Emmanuel Gyan, MD, PhD²⁵, Ibrahim Yakoub-Agha, MD, PhD²⁶, Krimo Bouabdallah, MD^{27*}, Eric Durot, MD^{28*} and Gandhi Damaj, MD²⁹

¹Institut d'Hématologie de Basse-Normandie, CHU, Caen, France

²Department of Clinical Hematology, University Hospital Montpellier, Montpellier, France

³Hematology Department, Centre Antoine Lacassagne, Nice, France

⁴Hematology, Toulouse University Hospital, Toulouse, France

⁵Amiens University hospital, Amiens, France

⁶Haematology, University Hospital, Strasbourg, France

⁷Hematology, University hospital, Rennes, France

⁸Department of Hematology, Nantes University Hospital, Nantes, France

⁹Dept. of hematology, Curie Institute, Hôpital René Huguenin, Saint-Cloud, France

¹⁰Hopital Rene Huguenin-Institut Curie, Saint Cloud, FRA

- ¹¹Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU, Université d'Auvergne, EA7283, CIC501, Clermont-Ferrand, Clermont Ferrand, France
- ¹²Oncopole Hopital Sud, Amiens, FRA
- ¹³Makassed General Hospital, Beirut, LBN
- ¹⁴Institut d'Hématologie de Basse-Normandie, Centre François Baclesse, Caen, France
- ¹⁵Hematology and Cell Therapy, Etablissement Hospitalier Universitaire (EHU) 1st November, Oran, Algeria
- ¹⁶Hematology, University Hospital, Dijon, France
- ¹⁷Hematology, CHU Grenoble, Grenoble, France
- ¹⁸Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts, CHU Limoges, Limoges, France
- ¹⁹Service des maladies du sang, Lille University Hospital, Lille, France
- ²⁰Hospital, Saint Quentin, France
- ²¹Service d'Hématologie, CH Boulogne sur Mer, BOULOGNE SUR MER, France
- ²²Oncologie hématologique et thérapie cellulaire, CHU Poitiers, Poitiers, France
- ²³Hematology, Brest University Hospital, Brest, France
- ²⁴Hematology, CHU, Besancon, France
- ²⁵Service d'Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire, Tours, France
- ²⁶Hematology, Hôpital HURIEZ UAM allogreffe de CSH, CHRU, Lille, France
- ²⁷Haematology, CHU de Bordeaux, Bordeaux, France
- ²⁸Department of Hematology, Centre Hospitalier Universitaire, Reims Cedex, FRA
- ²⁹Hematology Department, CHU Caen, Caen, France

895 Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group

Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: APL and other AML Specific Subsets

Lionel Ades, MD, PhD¹, Emmanuel Raffoux, MD^{2*}, Olivier Spertini³, Agnès Guerci, MD, PhD^{4*}, **Christian Recher, MD, PhD⁵**, Denis Guyotat^{6*}, Eric Deconinck, MD, PhD⁷, Thierry Lamy De La Chapelle^{8*}, Xavier Thomas, MD, PhD⁹, Dominique Bordessoule, MD, PhD¹⁰, Norbert Vey^{11,12}, Stéphane de Botton^{13*}, Arnaud Pigneux, MD^{14,15*}, Denis Caillot^{16*}, Jean-Yves Cahn, MD¹⁷, Patrice Chevallier, MD, PhD^{18*}, Jean-Francois Lambert, MD¹⁹, Claude Gardin, MD, PhD^{20*}, Herve Dombret^{21*}, Julie Lejeune^{22*}, Sylvie Chevret^{23*} and Pierre Fenaux, MD, PhD²⁴

¹Service d'Hématologie Séniors,, St Louis hospital, University Paris 7, Paris, France

²Hematology Department, Saint-Louis Hospital, Paris, France

³Hematology, CHUV, Lausanne, Switzerland

⁴Hématologie Clinique, CHU Nancy-Brabois, Vandoeuvre, France

⁵Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

⁶Hematology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France

⁷Hematology, INSERM UMR1098 - CHU Jean Minjot, Besancon, France

⁸Université de Rennes, Rennes Cedex 9, FRA

⁹Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

¹⁰Hematology, Limoges University Hospital, Limoges, France

¹¹Department of Hematology, Institut Paoli Calmettes, Marseille, France

¹²Aix Marseille Université, Marseille, France

¹³Institut Gustave Roussy, Villejuif, France

¹⁴Hôpitaux du Haut Lévêque CHU Bordeaux, Pessac, France

¹⁵INSERM UMR 1035, Bordeaux University, Bordeaux, France

¹⁶Hématologie Clinique, Dijon University Hospital, Dijon, France

¹⁷Hematology, CHU Grenoble Alpes, Grenoble, France

¹⁸Department of Hematology, Nantes University Hospital, Nantes, France

¹⁹Hospital of Nyon, Nyon, Switzerland

²⁰Hematology Department, Avicenne Hospital, APHP, University Paris 13, Bobigny, France

²¹Hematology, Hôpital Saint-Louis, Paris, France

²²Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Paris, France

²³Statistics St-Louis Hospital, Paris 7, Paris, France

²⁴Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France

4612 Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group

Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence Program: Oral and Poster Abstracts

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III

Bruno Royer, MD^{1*}, Momar Diouf^{2*}, **Murielle Roussel^{3*}**, Lionel Karlin, MD^{4*}, Cyrille Hulin^{5*}, Bertrand Arnulf, MD^{6*}, Margaret Macro^{7*}, Sylvie Cailleres^{8*}, Annie Brion, MD^{9*}, Sabine Brechignac, MD^{10*}, Karim Belhadj, MD^{11*}, Marie Lorraine Chretien^{12*}, Marc Wetterwald, MD, PhD^{13*}, Carine Chaletex^{14*}, Mourad Tiab^{15*}, Xavier Leleu¹⁶, Laurent Frenzel^{17*}, Laurent Garderet, MD¹⁸, Sylvain Choquet, MD^{19*}, Jean Gabriel Fuzibet^{20*}, Charles Dauriac, MD^{21*}, Luc-Matthieu Fornecker^{22*}, Lotfi Benboubker, MD, PhD^{23*}, Thierry Facon²⁴, Philippe Moreau^{25*}, **Hervé Avet-Loiseau^{26*}**, Stephane Minvielle^{27*} and Jean Pierre Marolleau, MD, PhD²⁸

¹Department of Hematology, University Hospital, Amiens, France

²University Hospital, Amiens, France

³Institut Universitaire du Cancer, toulouse, France

⁴Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France

⁵Bordeaux Hospital University Center (CHU), Bordeaux, France

⁶hematology department, Hôpital Saint Louis, Paris, France

⁷Haematology Department, Caen University Hospital, Caen, France

⁸Centre hospitalier, aix en Provence, France

⁹Hopital Jean Minjoz, Besancon, France

¹⁰Hopital Avicenne, bobigny, France

¹¹CHU Henri Mondor, Creteil, France

¹²CHRU Dijon, Dijon, France

¹³CHD Dunkerque, Dunkerque, France

¹⁴university hospital, Clermont Ferrand, France

¹⁵University Hospital, La Roche Sur Yon, France

¹⁶CHU DE POITIERS, POITIERS, France

¹⁷Hopital Necker, Paris, FRA

¹⁸Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

¹⁹Department of Clinical Hematology, Pitie-Salpetriere Hospital and Pierre et Marie Curie University, Paris, France

²⁰University hospital, Nice, France

²¹Hematology, CHU Rennes, Rennes, France

²²university hospital, strasbourg, France

²³Hôpital Bretonneau Service Hématologie et Thérapies Cellulaires, Centre Régional de Cancérologie Henry Kaplan CHRU de Tours, Tours, France

²⁴Hematology, CHRU Lille Hôpital Claude Huriez, Lille, Lille, France

²⁵Department of Hematology, Nantes University Hospital, Nantes, France

²⁶Institut Universitaire du Cancer and University Hospital, Unité de Génomique du Myélome, Toulouse, France

²⁷Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche Thérapeutique de l'Université de Nantes (IRT-UN), Nantes, France

²⁸Unit of Hematology, University Hospital, Amiens, France

4018 Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study

Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III

Patrice Chevallier, MD, PhD^{1*}, Sylvain Chantepie, MD^{2*}, **Françoise Huguet, MD^{3*}**, Emmanuel Raffoux, MD, PhD^{4*}, Xavier Thomas, MD, PhD⁵, Thibaut Leguay, MD^{6*}, Tony Marchand, MD^{7*}, Françoise Isnard, MD PhD^{8*}, Aude Charbonnier^{9*}, Sebastien Maury, MD, PhD^{10*}, Maria-Pilar Gallego-Hernanz, MD^{11*}, Nelly Robillard, PhD^{12*}, Thierry Guillaume, MD, PhD^{1*}, Pierre Peterlin, MD^{13*}, Alice Garnier, MD^{1*}, Fanny Rialland, MD^{14*}, Claire Le Houerou^{15*}, David M Goldenberg, ScD, MD¹⁶, William Wegener, MD, PhD¹⁶, Marie C Bene, PharmSciD, PhD^{17*} and Herve Dombret, MD¹⁸

¹Department of Hematology, Nantes University Hospital, Nantes, France

²Institut d'Hématologie de Basse-Normandie, CHU, Caen, France

³Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

⁴Hematology Department, Saint Louis Hospital, Paris, France

⁵CHU, Lyon, France

⁶Hematology, CHU Bordeaux, Pessac, France

⁷Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France

⁸Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

⁹Hematology department, Institut Paoli Calmettes, Marseille, France

¹⁰Hopital Henri Mondor, Creteil, FRA

¹¹Hematology Department, CHU, Poitiers, France

¹²Hematology Laboratory, Nantes University Hospital, Nantes, France

¹³HOPITAL HOTEL DIEU ET HME, NANTES CEDEX 1, FRA

¹⁴Oncopediatrics Department, Nantes University Hospital, Nantes, France

¹⁵Hematology Department, CHU, Nantes, France

¹⁶Immunomedics, Inc., Morris Plains, NJ

¹⁷Departement of Immunology, Centre Hospitalier Universitaire, Nantes, France

¹⁸Hopital Saint Louis, Paris, France

3470 Triage Scoring System Based on Early Post-Transplant Complications for Patients with Myelodysplastic Syndrome Requiring ICU after Allo-HCT: An SFGM-TC Study

Clinical Allogeneic Transplantation: Results

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Alexis Caulier^{1*}, Elodie Drumez^{2*}, Marie Robin, MD, PhD³, Didier Blaise, MD, PhD⁴, Yves Beguin, MD, PhD⁵, Mauricette Michallet, MD, PhD⁶, Patrice Chevallier, MD, PhD^{7*}, Jacques-Olivier Bay, MD, PhD⁸, Stéphane Vigouroux, MD^{9*}, Yohan Desbrosses^{10*}, Jérôme Cornillon, MD^{11*}, Stephanie Nguyen, MD, PhD^{12*}, Regis Peffault De Latour, MD, PhD^{13*}, Charles Dauriac, MD^{14*}, Bruno Lioure, MD^{15*}, Pierre Simon Rohrllich^{16*}, Martin Carré, MD^{17*}, Jean-Henri Bourhis, MD, PhD¹⁸, **Anne Huynh, MD^{19*}**, Felipe Suarez, MD, PhD²⁰, Federico Garnier, MD^{21*}, Alain Duhamel, MD, PhD^{22*} and Ibrahim Yakoub-Agha, M.D.- PhD²³

¹Hematology and cellular therapy, CHU Amiens Sud, Amiens Cedex 1, France

²Santé publique : épidémiologie et qualité des soins, Université de biostatistiques - CHU Lille, Lille, France

³Hematology / Transplantation, Saint-Louis Hospital, Paris, France

⁴Programme de Transplantation &Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

⁵Hematology, University and CHU of Liege, Liege, Belgium

⁶Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon, France

⁷Department of Hematology, Nantes University Hospital, Nantes, France

⁸Hematology department, CHU Clermont Ferrand, Clermont Ferrand, France

⁹University Hospital of Bordeaux, Bordeaux, France

¹⁰Department of hematology, CHU Jean Minjot, Besançon, France

¹¹Department of Hematology, Saint-Etienne University Hospital, Saint-Etienne, France

¹²Department of hematology, Pitie Salpetriere Hospital, Paris, France

¹³Hematology / Transplantation, Saint Louis Hospital, Paris, France

¹⁴Hematology, CHU Rennes, Rennes, France

¹⁵Hematology and Oncology, Hopital Hautepierre, Strasbourg, France

¹⁶Pediatric Oncology, CHU Nice, Nice, France

¹⁷Department of Hematology, CHU Grenoble, Grenoble, France

¹⁸Gustave Roussy Cancer Center, Villejuif, France

¹⁹Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole-CHU de Toulouse, Toulouse, France

²⁰Hôpital Universitaire Necker-Enfants Malades, Paris, France

²¹agence de la biomédecine, Saint Denis, France

²²Santé publique : épidémiologie et qualité des soins, Université de biostatistiques - CHRU Lille, Lille, France

²³Hematological department, Lille University Hospital, Lille, France

3920 Unique Long Non-Coding RNA Expression Signature in ETV6/RUNX1-Driven B-Cell Precursor Acute Lymphoblastic Leukemia

Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation

Program: Oral and Poster Abstracts

Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III

Farzaneh Ghazavi^{1,2*}, Barbara De Moerloose, MD^{2,3*}, Wouter Van Looke^{1*}, Annelynn Wallaert^{1*}, Alina Ferster⁴, Marleen Bakkus, PhD^{5*}, Genevieve Plat, MD^{6*}, Eric Delabesse, PharmD, PhD^{7*}, Anne Uyttebroeck^{8*}, Filip Van Nieuwerburgh, PharmD, Prof^{9*}, Dieter Deforce, PharmD, Prof^{9*}, Nadine van Roy, MD, Prof^{1,3*}, Frank Speleman, Prof^{1,3*}, Yves Benoit¹⁰, Tim Lammens^{2,3*} and Pieter van Vlierberghe, Prof^{1,3*}

¹Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium

²Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

³Cancer Research Institute Ghent (CRIG), Ghent, Belgium

⁴Department of Hemato-Oncology, Huderf, Brussels, Belgium

⁵Department of Hematology, University Hospital Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium

⁶Department of Hematology, CHU Toulouse, Toulouse, France

⁷Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France

⁸Department of Pediatric Hemato-Oncology, University Hospital Leuven, Leuven, Belgium

⁹Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium

¹⁰Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, University Hospital Ghent, Ghent, Belgium

196 The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Prognostic Factors

Brian A Walker, PhD¹, Mehmet K. Samur, PhD^{2*}, Konstantinos Mavrommatis^{3*}, Cody Ashby, PhD^{1*}, Christopher P Wardell, PhD^{1*}, Maria Ortiz, PhD^{4*}, Fadi Towfic^{5*}, Caleb K. Stein, MS^{1*}, Michael A Bauer, PhD^{1*}, Michael Amatangelo, PhD^{5*}, Giovanni Parmigiani, PhD^{6*}, Zhinuan Yu, PhD^{5*}, Matthew Trotter^{4*}, Hervé Avet-Loiseau^{7,8*}, Graham H Jackson, MD, PhD⁹, Kenneth C. Anderson¹⁰, Anjan Thakurta, Ph.D.^{5*}, Nikhil C. Munshi, MD¹⁰ and Gareth J Morgan, MD, PhD¹

¹Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

²The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

³Celgene Corporation, San Francisco, CA

⁴Celgene Institute for Translational Research Europe, Celgene Corporation, Seville, Spain

⁵Celgene Corporation, Summit, NJ

⁶Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

⁷Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale, Toulouse, France

⁸IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

⁹Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

¹⁰Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

4230 Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013

Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies

Program: Oral and Poster Abstracts

Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Poster III

Inès Bousset^{1*}, Caroline Algrin, MD^{1*}, Julien Rossignol, MD^{2*}, Eric Durot, MD^{3*}, Sarah Guenounou^{4*}, Antoine Bonnet^{5*}, Jeremy Delage, MD^{6*}, Emmanuel Gyan, MD, PhD⁷, Fontanet Bijou, MD⁸, Noel Milpied, MD⁹, Adrien Chauchet, MD^{10*}, Adrien Tempescul, MD^{11*}, Gandhi Damaj, MD¹², Arnaud Jaccard, MD, PhD^{13*}, Jerome Cornillon, MD^{14*}, Norbert Ifrah¹⁵, Veronique Leblond¹⁶ and Sylvain Choquet, MD^{1*}

¹Department of Clinical Hematology, Pitie-Salpetriere Hospital and Pierre et Marie Curie University, Paris, France

²Department of Hematology, Necker Children's hospital, APHP, Paris, France

³Department of Hematology, Centre Hospitalier Universitaire, Reims Cedex, FRA

⁴Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

⁵Department of Hematology, University of Nantes, Nantes, France

⁶CHU Lapeyronie, Département d'Hématologie Clinique, Montpellier, FRA

⁷Department of Clinical Hematology, CHRU de Tours, Tours, France

⁸Institut Bergonie, Bordeaux, France

⁹Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Haut-Lévêque, Bordeaux, France

¹⁰Hematology, CHU, Besancon, France

¹¹Haematology, University Hospital, Brest, France

¹²Hematology Department, CHU Caen, Caen, France

¹³Department of Hematology, Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts, CHU Limoges, Limoges, France

¹⁴Department of Hematology, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France

¹⁵Hematology, Angers University Hospital, Angers, France

¹⁶Department of Clinical Hematology, AP-HP Hôpital Pitié-Salpêtrière, Paris, France

2555 Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists

Disorders of Platelet Number or Function

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster II

Matthieu Mahevas, MD, PhD^{1*}, Sandrine Van Eeckhoudt, MD^{2*}, Guillaume Moulis, MD, PhD^{3*}, Christine Dosquet, MD, PhD^{4*}, Marc Michel, MD, PhD^{5*}, Nicolas Limal, MD^{6*}, Laetitia Languille^{7*}, Sawsaneh Alkaeir, MD^{8*}, Philippe Bierling, MD, PhD^{9*}, Antoine Dossier, MD^{10*}, Frédéric Duriez, MD^{11*}, Lionel Galicier, MD^{12*}, Anne-Sophie Morin, M.D.^{13*}, Jérôme Tamburini, MD, PhD^{14*}, Driss Chaoui, MD^{15*}, Didier Bouscary, MD, PhD^{16*}, Ahmad AL Jijakli, MD^{17*}, Mehdi Khellaf, MD^{18*}, Ioana Vaida, MD^{19*}, Bertrand Godeau, MD, PhD^{20*} and Christine Chomienne, MD, PhD²¹

¹Internal Medicine, French referral center for adult's immune cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France

²Internal Medicine., French Referral Center for Adult's Immune Cytopenia. Henri Mondor. AP-HP. UPEC University., Créteil, France

³CIC 1436, Toulouse University Hospital, Toulouse, France

⁴Service de Biologie Cellulaire, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Saint Louis, INSERM UMR_S1131, Institut Universitaire d'Hématologie, Paris, France, Paris, France

⁵Henri Mondor Hospital, Assistance Publique Hopitaux de Paris, Paris XII universi, Creteil, FRA

⁶Internal Medicine., French Referral Center for Adult's Immune Cytopenia. Henri Mondor Hospital. AP-HP. UPEC University., Créteil, France

⁷French Referral center for Adult's Immune Cytopenia. henri Mondor Hospital. UPEC University., Créteil, France

⁸UMRS-1131, INSERM Hôpital Saint Louis, Paris, France

⁹Internal Medicine, French Referral center for Adult's Immune Cytopenia. Henri Mondor Hospital. AP-HP. UPEC University, Créteil, France

- ¹⁰Department of internal Medicine, Hôpital Bichat, Paris, France
¹¹Oncology - Hematology, Les Hôpitaux de Chartres., Chartres, France
¹²St-Louis University Hospital, Paris, France
¹³Department of Internal Medicine, Hopital Jean Verdier, Bondy, France
¹⁴Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
¹⁵Hematology, CH Victor Dupouy, Argenteuil, France
¹⁶Hematology Department, Cochin University Hospital, AP-HP, Paris, France
¹⁷CH Argenteuil, Argenteuil, France
¹⁸Henri Mondor Hospital, AP-HP, UPEC University, Creteil, France
¹⁹Hematology, CH Pontoise, Pontoise, France
²⁰Internal Medicine, French Referral Center for Adult's Immune Cytopenia. Henri Mondor Hospital. AP-HP. UPEC University., Créteil, France
²¹UMRS-1131, INSERM Hopital Saint-Louis, Paris, France

3485 Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of Bone Marrow Transplantation and Cellular Therapy)

Clinical Allogeneic Transplantation: Results

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Jordan Gauthier, MD^{1*}, Luca Castagna, MD^{2*}, Federico Garnier, MD^{3*}, Thierry Guillaume, MD, PhD^{4*}, Gerard Socie, MD, PhD⁵, Sebastien Maury, MD, PhD^{6*}, Natacha Maillard, MD^{7*}, Reza Tabrizi, MD⁸, Tony Marchand, MD^{9*}, Jean Valere Malfuson^{10*}, Anne-Claire Gac, MD^{11*}, Emmanuel Gyan, MD, PhD¹², Melanie Mercier, MD^{13*}, Yves Beguin, MD, PhD¹⁴, Jeremy Delage, MD^{15*}, Pascal Turlure, MD^{16*}, Ambroise Marçais, MD^{17*}, Stephanie Nguyen, MD, PhD^{18*}, Remy Dulery, MD^{19*}, Jacques Olivier Bay, MD^{20*}, **Anne Huynh, MD^{21*}**, Etienne Daguindau, MD^{22*}, Caroline Régné^{23*}, Mauricette Michallet, MD, PhD²⁴, Regis Peffault De La Tour, MD, PhD^{25*}, Ibrahim Yakoub-Agha, MD, PhD²⁶ and Didier Blaise, MD, PhD²⁷

¹CHRU Lille Hopital Huriez, Lille, France

²Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy

³agence de la biomédecine, Saint Denis, France

⁴Department of Hematology, Nantes University Hospital, Nantes, France

⁵St-Louis Hospital, Paris, France

⁶Hopital Henri Mondor, Creteil, FRA

⁷Bone Marrow Transplant Unit Clinical Hematology, Hopital La Miletrie, Poitiers, France

⁸Hematology, University Hospital of Bordeaux, Pessac, France

⁹Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France

¹⁰Hôpital d'instruction des armées Percy, Paris Cedex 10, FRA

¹¹CHU Caen, Caen, France

¹²Service d'Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire, Tours, France

¹³Haematology, CHU Angers, Angers, France

¹⁴Hematology, University and CHU of Liege, Liege, Belgium

¹⁵CHU Lapeyronie, Département d'Hématologie Clinique, Montpellier, FRA

¹⁶Hematology, CHU Limoges, Limoges, France

¹⁷Service d'hématologie and Imagine Institute, Necker Hospital, Paris, France

¹⁸Department of hematology, Pitie Salpetriere Hospital, Paris, France

¹⁹Hematology and Cellular Therapy, Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France

²⁰Hematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France

²¹Institut Universitaire du Cancer, Oncopole IUCT, Toulouse, France

²²Hematology Department, Besançon University Department, Besançon, France

²³Department of Hematology, University CHU Grenoble, Grenoble, France

²⁴Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon, France

²⁵Hematology - Bone Marrow Transplantation, Hopital St Louis, Paris, France

²⁶Hematology, Hôpital HURIEZ UAM allogreffe de CSH, CHRU, Lille, France

²⁷Programme de Transplantation &Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

903 Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Clinical Trials of Novel Drugs and Combinations in AML

Farhad Ravandi, MD¹, Ellen K. Ritchie, MD², Hamid Sayar, MD^{3*}, Jeffrey E. Lancet, MD⁴, Michael Craig, MD⁵, Norbert Vey, MD, PhD⁶, Stephen A. Strickland⁷, Gary J. Schiller, MD⁸, Elias J. Jabbour, MD⁹, Harry P. Erba, MD, PhD¹⁰, Arnaud Pigneux, MD^{11*}, Heinz-August Horst, MD, PhD¹², **Christian Recher, MD, PhD¹³**, Virginia M. Klimek, MD¹⁴, Jorge E. Cortes, MD¹⁵, Gail J. Roboz¹⁶, Adam R. Craig, MD, PhD¹⁷, Renee Ward, MD, PhD^{17*}, Jennifer Smith, PhD^{17*}, Hagop M. Kantarjian, MD¹⁸ and Robert K. Stuart, MD¹⁹

¹University of Texas MD Anderson Cancer Center, Houston, TX

²Weill Cornell Medical Center, New York, NY

³Indiana University Cancer Center, Indianapolis, IN

⁴Moffitt Cancer Center, University of South Florida, Tampa, FL

⁵West Virginia University, Morgantown, WV

⁶Institut Paoli-Calmettes, Marseille, France

⁷Vanderbilt-Ingram Cancer Center, Nashville, TN

⁸University of California Los Angeles, Los Angeles, CA

⁹Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

¹⁰Division of Hematology and Oncology, University of Alabama, Birmingham, AL

¹¹Hôpital Haut Lévêque-CHU de Bordeaux, Pessac Cedex, France

¹²II. Medizinische Klinik und Poliklinik im Städtischen Krankenhaus, Kiel, Germany

¹³Hôpital Purpan-CHU de Toulouse, Toulouse, France

¹⁴303 East 60th Street Apt 271, Memorial Sloan Kettering Cancer Center, New York City, NY

¹⁵University of Texas M.D. Anderson Cancer Center, Houston, TX

¹⁶Division of Hematology and Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY

¹⁷Sunesis Pharmaceuticals, Inc., South San Francisco, CA

¹⁸Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

¹⁹Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

4637 Extending Autologous Hematopoietic Stem Cell Transplantation As First Line Treatment in Multiple Myeloma Patients with Severe Renal Impairment: A Retrospective Study of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

Clinical Autologous Transplantation: Results

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster III

Karine Augeul-Meunier, MD^{1*}, Denis Caillot^{2*}, Anne-Marie Stoppa³, Lionel Karlin, MD^{4*}, Lofti Benboubker^{5*}, Natacha Maillard, MD^{6*}, Mohamad Mohty, MD, PhD⁷, Ibrahim Yakoub-Agha, MD^{8*}, Jacques-Olivier Bay, MD, PhD⁹, Caroline Bonmati, MD^{10*}, Claude-Eric Bulabois, MD^{11*}, **Anne Huynh, MD^{12*}**, Melanie Mercier, MD^{13*}, Laurent Frenzel, MD, PhD^{14*}, **Hervé Avet-Loiseau^{15*}** and Jerome Cornillon, MD^{1*}

¹Hematology department, Institut de Cancerologie Lucien Neuwirth, Saint-Priest-en-Jarez, France

²Hématologie Clinique, Dijon University Hospital, Dijon, France

³Institut Paoli Calmettes, Marseille, France

⁴Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France

⁵CHU Tours Hopital Bretonneau, Tours, France

⁶Bone Marrow Transplant Unit Clinical Hematology, Hopital La Miletrie, Poitiers, France

⁷Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

⁸Hematology, Lille, France

⁹Hematology department, CHU Clermont Ferrand, Clermont Ferrand, France

¹⁰Hematology, CHU Nancy, Nancy, France

¹¹Hematology, CHU Grenoble, Grenoble, France

¹²Institut Universitaire du Cancer Toulouse, Oncopole, Toulouse, France

¹³Haematology, CHU Angers, Angers, France

¹⁴Department of Clinical Hematology, Hopital Necker, AP-HP, Paris, France

¹⁵IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

1162 Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence Program: Oral and Poster Abstracts

Type: Oral

Session: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Immunotherapy to Prevent or Treat Relapse After Transplantation

Thierry Guillaume, MD, PhD^{1*}, Ibrahim Yakoub-Agha, M.D.- PhD², Reza Tabrizi, MD³, **Cecile Borel, MD^{4*}**, Patrice Chevallier, MD, PhD^{1*}, Leonardo Magro, MD^{2*}, Stéphane Vigouroux, MD^{5*}, Pierre Peterlin, MD^{1*}, Alice Garnier, MD^{1*}, Marie-Thérèse Rubio, MD, PhD^{6*}, **Anne Huynh, MD^{7*}**, Noel Milpied, MD PhD⁸, Philippe Moreau^{1*} and Mohamad Mohty, MD, PhD⁹

¹Department of Hematology, Nantes University Hospital, Nantes, France

²Hematological department, Lille University Hospital, Lille, France

³Hematology, University Hospital of Bordeaux, Pessac, France

⁴Hematology, Toulouse University Hospital, Toulouse, France

⁵University Hospital of Bordeaux, Bordeaux, France

⁶Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

⁷Department Hématologie, Hôpital de Purpan, Toulouse, France

⁸Service d'Hématologie et de Thérapie Cellulaire, CHU Haut-Leveque and University of Bordeaux, Bordeaux, France

⁹Hematology, Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France

145 Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group

Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies

Program: Oral and Poster Abstracts

Type: Oral

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Therapeutic Approaches to Mantle Cell Lymphoma

Steven Le Gouill, MD, PhD^{1,2*}, Catherine Thieblemont, MD, PhD³, **Lucie Oberic, MD^{4*}**, Anne Moreau, MD^{5*}, Krimo Bouabdallah, MD^{6*}, Emmanuel Gyan, MD, PhD⁷, Gandhi Damaj^{8*}, Vincent Ribrag, MD⁹, Pierre Feugier, MD, PhD^{10*}, Olivier Casanovas, MD^{11*}, Hacene Zerazhi, MD^{12*}, Corinne Haioun, MD, PhD¹³, Hervé Tilly, MD, PhD¹⁴, Olivier Tournilhac, MD, PhD^{15*}, Herve Maisonneuve, MD^{16*}, Philippe Solal-Celigny, MD¹⁷, Luc Mathieu Fornecker, MD, PhD^{18*}, Eric W Van Den Neste, MD, PhD¹⁹, Danielle Canoni, MD²⁰, Gilles Salles, MD, PhD²¹, Thierry Lamy, MD PhD²², Marie-Christine Bene, PharmD^{23*}, Remy Gressin, MD²⁴ and Olivier Hermine, MD, PhD^{25*}

¹Department of hematology, Nantes university Hospital and UMR892 INSERM, Nantes, France

²CHU de Nantes, INSERM UMR 892 équipe 10, Nantes, France

³Hôpital Saint-Louis, Paris, France

⁴Department of Hematology, Purpan University Hospital, Toulouse, France

⁵Department of Pathology, Nantes University Hospital, Nantes, France

⁶Haematology, CHU de Bordeaux, Bordeaux, France

⁷Service d'Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire, Tours, France

⁸CHU d'Amiens, Amiens, France

⁹Gustave Roussy cancer campus, Villejuif, France

¹⁰CHU et INSERM 954, Nancy Université, Vandoeuvre Les Nancy, France

¹¹Hematology Department, Hopital Le Bocage, CHU Dijon, Dijon, France

¹²hematology, CHG Avignon, Avignon, France

- ¹³Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France
- ¹⁴INSERM U918, Centre Henri Becquerel, Rouen, France
- ¹⁵Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU, Université d'Auvergne, EA7283, CIC501, Clermont-Ferrand, Clermont Ferrand, France
- ¹⁶Oncology and Hematology Department, CH, La Roche-sur-Yon, France
- ¹⁷Centre Jean Bernard, Le Mans, France
- ¹⁸Haematology, University Hospital, Strasbourg, France
- ¹⁹Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
- ²⁰Pathology Department, Hopital Necker, Paris, France
- ²¹Hématologie, Hospices Civils de Lyon - Université de Lyon - UMR CNRS5239, Pierre-Benite, France
- ²²INSERM U917, CHU Pontchaillou, Rennes, France
- ²³Hopital Hotel Dieu, Laboratoire d'Hématologie, Nantes, France
- ²⁴Hematology, CHU Grenoble, Grenoble, France
- ²⁵Hematology Department, Necker University Hospital, AP-HP, Paris, France

3467 Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Clinical Allogeneic Transplantation: Results

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster II

Charles Craddock, MD, PhD¹, Jurjen Versluis^{2*}, Myriam Labopin^{3*}, Gerard Socie⁴, **Anne Huyn^{5*}**, Eric Deconinck, MD, PhD⁶, Liisa Volin, MD, PhD⁷, Noel Milpied, MD⁸, Jean Henri Bourhis, MD, PhD^{9*}, Alessandro Rambaldi, MD¹⁰, Patrice Chevallier, MD, PhD^{11*}, Didier Blaise, MD, PhD¹², Manz Markus^{13*}, Edo Vellenga, MD, PhD¹⁴, Marie Christiane Vekemans^{15*}, Johan Maertens, MD, PhD^{16*}, Jakob R. Passweg¹⁷, Christoph Schmid^{18*}, G J. Ossenkoppele¹⁹, Paresch Vyas, MD, PhD²⁰, Bob Löwenberg, MD, PhD²¹, Mohamad Mohty, MD, PhD²², Jan J. Cornelissen, MD, PhD²³ and Arnon Nagler, MD, MSc²⁴

¹Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom

²Erasmus University Medical Center, Rotterdam, Netherlands

³Department of Hematology and Cell Therapy, Saint Antoine Hospital, Paris, France

⁴Department of Hematology - BMT, Hopital St. Louis, Paris, France

⁵Institut Universitaire Du Cancer, Toulouse, France

⁶Hematology, INSERM UMR1098 - CHU Jean Minjoz, Besancon, France

⁷Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland

⁸Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Haut-Lévêque, Bordeaux, France

⁹Gustave Roussy Cancer Center, Villejuif, France

¹⁰Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

¹¹Department of Hematology, Nantes University Hospital, Nantes, France

¹²Programme de Transplantation & Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

¹³University of Zurich, Zurich, Switzerland

¹⁴Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University Groningen, Groningen, Netherlands

¹⁵University, Bruxelles, BEL

¹⁶Department of Hematology, University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium

¹⁷for the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation, (SAA WP-EBMT), Switzerland

¹⁸2. Medizinische Klinik, Klinikum Augsburg, Augsburg, Germany

¹⁹Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

²⁰MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine and Department of Haematology, University of Oxford, Oxford, United Kingdom

²¹Editor-in-Chief, Blood, Erasmus University Medical Center, Rotterdam, Netherlands

²²Department of Haematology, EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France

²³Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

²⁴Division of Hematology, Sheba Medical Center, Ramat Gan, Israel

238 A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Progression

Nikhil C. Munshi, MD¹, Joaquin Martinez-Lopez^{2*}, Victoria Carlton, Ph.D.^{3*}, Stephanie Minvielle^{4*}, Yu-Tzu Tai, PhD⁵, Mariateresa Fulciniti, PhD⁶, Mehmet K. Samur, PhD^{6*}, Paul G. Richardson, MD⁷, Michel Attal⁸, Philippe Moreau^{9*}, Florence Magrangeas^{4*}, Kenneth C. Anderson, MD¹⁰, Malek Faham, MD, PhD³ and **Hervé Avet-Loiseau^{11*}**

¹The Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

²Hospital-12-de-October, Madrid, Spain

³Adaptive Biotechnologies Corp, South San Francisco, CA

⁴Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche Thérapeutique de l'Université de Nantes (IRT-UN), Nantes, France

⁵Harvard Medical School, the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

⁶The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁷Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁸Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

⁹Department of Hematology, Nantes University Hospital, Nantes, France

¹⁰Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

¹¹IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

116 Analysis of Mutational Signatures Suggest That AID Has an Early and Driver Role in Multiple Myeloma

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Biologic Insights from Genetics

Francesco Maura^{1,2,3*}, Niccolo Bolli, MD^{1,2,3*}, Stephane Minvielle^{4*}, Dominik Gloznik^{3*}, Raphael Szalat^{5*}, Anthony Fullam^{3*}, Inigo Martincorena^{3*}, Mehmet Kemal Samur, PhD^{6*}, Patrick Tarpey^{3*}, Helen Davies^{3*}, Kevin J. Dawson^{3*}, Serena Nik-Zainal^{3*}, Moritz Gerstung^{7*}, Jorge Zamora^{3*}, Yu-Tzu Tai^{8*}, Cristiana Carniti^{9*}, Florence Magrangeas^{10*}, Philippe Moreau^{10*}, Paolo Corradini^{1,2}, Kenneth Anderson^{8*}, David Wedge^{3,11*}, **Hervé Avet-Loiseau^{4*}**, Peter Campbell^{3*} and Nikhil Munshi^{8,12}

¹Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

²Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

³Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

⁴Centre Hospitalier Universitaire Rangueil, Unité de Genomique du Myelome, Toulouse, France

⁵Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁶Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁷European Bioinformatics Institute, European Molecular Biology Laboratory (EMBL-EBI), Hinxton, United Kingdom

⁸Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁹Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milano, Milan, Italy

¹⁰Université de Nantes, INSERM UMR 892, CNRS UMR 6299, Nantes, France

¹¹University of Oxford, Big Data Institute, Oxford, United Kingdom

¹²Boston Veterans Administration Healthcare System, West Roxbury, MA

243 Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Myeloma: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma: Therapy, excluding Transplantation: Clinical Studies, Minimal Residual Disease, and Biomarkers

Alessandra Di Bacco, PhD^{1*}, Nizar J. Bahlis, MD^{2,3}, Nikhil C Munshi, MD⁴, **Hervé Avet-Loiseau^{5*}**, Tamás Masszi, MD^{6*}, Luísa Viterbo, MD^{7*}, Ludek Pour, MD, PhD^{8*}, Peter Ganly, BMBCh, PhD^{9*}, Michele Cavo, MD^{10*}, Christian Langer, MD¹¹, Shaji Kumar, MD¹², S. Vincent Rajkumar, MD¹², Deborah Berg, RN, MSN¹, Jianchang Lin, PhD^{1*}, Bin Li^{1*}, Sunita Badola^{1*}, Lei Shen^{1*}, Jacob Zhang^{1*}, Ling Wang, PhD^{1*}, Dixie-Lee Esseltine, MD¹, Katarina Luptakova¹, Helgi van de Velde, MD, PhD^{1*}, Paul G. Richardson, MD¹³ and Philippe Moreau^{14*}

¹Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA

²University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada

³University of Calgary, Calgary, AB, Canada

⁴Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA

⁵Hematology, IUC-Oncopole, Toulouse, France

⁶Department of Haematology and Stem Cell Transplantation, St. Istvan and St. Laszlo Hospital of Budapest, Budapest, Hungary

⁷Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE), Porto, Portugal

⁸Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

⁹Department of Haematology, Christchurch Hospital, Christchurch, New Zealand

¹⁰Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy

¹¹University Hospital of Ulm, Ulm, Germany

¹²Division of Hematology, Mayo Clinic, Rochester, MN

¹³Dana-Farber Cancer Institute, Boston, MA

¹⁴Hematology, University Hospital Hôtel Dieu, Nantes, France

3186 Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Myelodysplastic Syndromes—Clinical Studies

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Saskia Langemeijer, MD, PhD^{1,2*}, Louise De Swart, MD^{3*}, Ge Yu, MSc.^{4*}, Alex Smith^{4*}, Simon Crouch, PhD^{4*}, Tom Johnston, PhD^{5*}, Pierre Fenaux, MD, PhD⁶, Argiris Symeonidis⁷, Jaroslav Cermak⁸, Eva Hellstrom-Lindberg, MD, PhD⁹, Guillermo Sanz, MD¹⁰, Reinhard Stauder, MD^{11*}, Luca Malcovati, MD¹², Ulrich Germing^{13*}, Mette Skov Holm^{14*}, Moshe Mittelman, MD¹⁵, Krzysztof Madry, MD, PhD^{16*}, Aurelia Tatic, MD^{17*}, Antonio Almeida, MD, PhD^{18*}, Aleksandar Savic¹⁹, Sophie Park, MD, PhD²⁰, **Odile Beyne-Rauzy, MD^{21*}**, Raphaël Itzykson, MD, PhD²², Corine van Marrewijk, Ph.D.^{3*}, David Bowen, MD, PhD^{23*} and Theo de Witte, MD, PhD²⁴

¹Radboud University medical Center, Nijmegen, Netherlands

²Radboudumc, Nijmegen, Netherlands

³Hematology, Radboudumc, Nijmegen, Netherlands

⁴Epidemiology and Cancer Statistics Group, University of York, York, United Kingdom

⁵University of York, York, United Kingdom

⁶Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France

⁷Department of Internal Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece

⁸Institute of Hematology and Blood Transfusion, Prague, Czech Republic

⁹Center for Hematology and Regenerative Medicine (HERM), Department of Medicine, Karolinska Institutet, Stockholm, Sweden

¹⁰Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

¹¹Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

¹²Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Pavia, Italy

¹³Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

¹⁴Dept of Hematology, Aarhus University Hospital, Aarhus, Denmark

¹⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

¹⁶Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland

¹⁷Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania

¹⁸Serviço de Hematologia, Lisbon, Portugal

¹⁹Clinic of Hematology, Clinical Center of Vojvodina, Novi Sad, Serbia

²⁰Cochin Hospital, University Paris 5, Paris, France

²¹Service d'hématologie, Centre Hospitalier Universitaire de Purpan, Toulouse, France

²²UMR7212/U944, Institut National de la Santé et de la Recherche Médicale, Saint-Louis Institute, University Paris 7, Paris, France

²³St James's Institute of Oncology, Leeds, United Kingdom

²⁴Nijmegen Center for Molecular Life Sciences, Dep. of Tumor Immunology, Radboud University of Nijmegen Medical Centre, Nijmegen, Netherlands

2776 Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol – a Graall Study

Acute Lymphoblastic Leukemia: Clinical Studies

Program: Oral and Poster Abstracts

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II

Corentin Orvain^{1*}, Marie Balsat, MD^{2*}, Véronique Lhéritier^{3*}, Emmanuelle Tavernier^{4*}, Jean-Pierre Marolleau, MD, PhD^{5*}, Thomas Pabst, MD, PhD^{6,7}, Patrice Chevallier, MD, PhD^{8*}, Noémie De Gunzburg, MD^{9*}, Victoria Cacheux^{10*}, **Françoise Huguet, MD**^{11*}, Sylvain Chantepie, MD^{12*}, Denis Caillot^{13*}, Yves Chalandon, MD^{6,14}, Jamilé Frayfer, MD^{15*}, Caroline Bonmati, MD^{16*}, Nicolas Boissel, MD, PhD¹⁷, Hervé Dombret, MD, PhD¹⁷, Norbert Ifrah¹⁸ and Mathilde Hunault-Berger, MD, PhD^{1*}

¹Maladies du Sang, Angers University Hospital, Angers, France

²Hématologie Clinique, Lyon-Sud Hospital, Pierre Benite, France

³GRAALL Coordination, Lyon-Sud University Hospital, Pierre-Bénite, France

⁴Hematology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France

⁵Hématologie Clinique, Amiens University Hospital, Amiens, France

⁶Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

⁷Department of Hematology, Bern University Hospital, Bern, Switzerland

⁸Department of Hematology, Nantes University Hospital, Nantes, France

⁹Hématologie Oncologie, Versailles Hospital, Versailles, France

¹⁰Hematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France

¹¹Hématologie, Toulouse Cancer University Institute, Toulouse, France

¹²Institut d'Hématologie, Caen University Hospital, Caen, France

¹³Hématologie Clinique, Dijon University Hospital, Dijon, France

¹⁴Division of Hematology, Geneva University Hospitals, Geneva, Switzerland

¹⁵Hématologie, Meaux Hospital, Meaux, France

¹⁶Hématologie, Nancy University Hospital, Nancy, France

¹⁷Hématologie Adulte, Saint-Louis Hospital, APHP, Paris, France

¹⁸Hematology, Angers University Hospital, Angers, France

3271 Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II

Davine Hofste op Bruinink, MD, MSc^{1*}, Hoogenboezem Remco, MSc^{1*}, Mathijs A. Sanders, PhD^{1*}, Christopher P Wardell, PhD^{2*}, Cody Ashby, PhD^{2*}, Eric M.J. Bindels, PhD^{3*}, Claudia Erpelinck-Verschueren, BSc^{1*}, Paulette van Strien, BSc^{1*}, Jasper Koenders, BSc^{1*}, François G. Kavelaars, BSc^{3*}, Jie He, PhD^{4*}, Mark Bailey, MSc^{4*}, Tariq I Mughal, MD, FRCP⁴, Kristine Misund, PhD^{5*}, Berna Beverloo, PhD^{6*}, Bronno van der Holt, PhD^{7*}, Ivo Touw, PhD¹, Anders Waage, MD PhD⁵, **Hervé Avet-Loiseau^{8*}**, Graham H Jackson, MD, PhD⁹, Gareth J Morgan, MD, PhD², Brian A Walker, PhD² and Pieter Sonneveld, MD PhD¹

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

²Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

³Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

⁴Foundation Medicine, Inc., Cambridge, MA

⁵KG Jebsen Center for Myeloma Research, Norwegian University of Science and Technology, Trondheim, Norway

⁶Department of Clinical Genetics, Erasmus MC, Rotterdam, Netherlands

⁷Department of Hematology, Erasmus MC Cancer Institute, HOVON Data Center, Rotterdam, Netherlands

⁸IUC-Oncopole, Unité de Génomique du Myélome, Toulouse, France

⁹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom

1816 Clinical Spectrum, Evolution and Management of Autoimmune Cytopenia Associated with Angioimmunoblastic T-Cell Lymphoma: A Retrospective, Multicenter Study

Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

Etienne Crickx, MD^{1*}, Radjiv Goulabchand, MD^{2*}, Claire Fieschi, MD, PhD^{3*}, Lionel Galicier, MD^{4*}, Paul Coppo, MD, PhD^{5*}, Veronique Meignin, MD^{6*}, Richard Delarue, MD⁷, Olivier Casasnovas, MD^{8*}, Veronique Leblond, MD, PhD^{9*}, **Guillaume Moulis, MD, PhD^{10*}**, Marc Michel, MD, PhD^{11*}, Jehan Dupuis, MD^{12*}, Fabien Le Bras, MD^{13*}, Virginie Fataccioli, PhD^{14*}, Corinne Haioun, MD, PhD¹⁵, Bertrand Godeau, MD, PhD^{11*}, Philippe Gaulard, MD, PhD^{16*} and Matthieu Mahevas, MD, PhD^{11*}

¹Service de Médecine interne, Hôpital Henri Mondor, Créteil, France

²Service de Médecine interne, Hôpital Saint Eloi, Montpellier, France

³Service d'immunologie clinique, Hôpital Saint Louis, Paris, France

⁴St-Louis University Hospital, Paris, France

⁵Hematology and Cellular Therapy, Saint Antoine Hospital, Paris, France

⁶Pathology, APHP, Hopital Saint-Louis, Paris, France

⁷Hematology Department, Necker University Hospital, AP-HP, Paris, France

⁸Hematology Department, Hopital Le Bocage, CHU Dijon, Dijon, France

⁹Department of Haematology, Hôpital de la Pitié-Salpêtrière, Paris, France

¹⁰Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-, Toulouse, France

¹¹Internal Medicine, French referral center for adult's immune cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France

¹²Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor, CRETEIL, France

¹³Service d'Hématologie Lymphoïde, Hôpital Henri Mondor, Créteil, France

¹⁴Inserm U955, APHP Hospital Henri Mondor, Creteil, France

¹⁵Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France

¹⁶department of pathology, APHP, Groupe Hospitalier Mondor, CRETEIL, France

2088 Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Niccolo Bolli, MD^{1,2,3*}, Francesco Maura^{1,2,3*}, Stephane Minvielle^{4*}, Dominik Gloznik^{1*}, Raphael Szalat^{5*}, Anthony Fullam^{1*}, Mehmet Kemal Samur, PhD^{6*}, Patrick Tarpey^{1*}, Helen Davies^{1*}, Inigo Martincorena^{1*}, Kevin J. Dawson^{1*}, Thomas Mitchell^{1*}, Jorge Zamora^{1*}, Cristiana Carniti^{7*}, Yu-Tsu Tai^{8*}, Florence Magrangeas^{9*}, Philippe Moreau^{9*}, Paolo Corradini^{2,3*}, Kenneth Carl Anderson^{8*}, David Wedge^{1,10*}, **Hervé Avet-Loiseau^{4*}**, Peter Campbell^{1*} and Nikhil Munshi, MD^{11,12}

- ¹Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
²Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
³Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
⁴Centre Hospitalier Universitaire Rangueil, Unité de Genomique du Myelome, Toulouse, France
⁵Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milano, Milan, Italy
⁸Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹Université de Nantes, INSERM UMR 892, CNRS UMR 6299, Nantes, France
¹⁰University of Oxford, Big Data Institute, Oxford, United Kingdom
¹¹Dana–Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA
¹²Boston Veterans Administration Healthcare System, West Roxbury, MA

3458 Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular Therapy Study

Clinical Autologous Transplantation: Results

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster II

Remy Dulery, MD^{1*}, Oumedaly Reman, MD², Ariane Boumemdil^{3*}, Reda Bouabdallah, MD⁴, Pauline Brice, MD⁵, Thomas Gastinne, MD^{6*}, Reza Tabrizi, MD⁷, Philippe Quittet, MD⁸, **Anne Huynh, MD^{9*}**, Gilles Salles, MD, PhD¹⁰, Helene Monjanel^{11*}, Aspasia Stamatoullas, MD^{12*}, Jean-Henri Bourhis, MD, PhD¹³, Caroline Bonmati, MD^{14*}, Sylvie Francois, MD^{15*}, Stephanie Nguyen Quoc, MD PhD^{16*}, Jacques Olivier Bay, MD^{17*}, Jean-Yves Cahn, MD¹⁸, Pascal Turlure, MD^{19*}, Charles Dauriac, MD^{20*}, Mohamad Mohty, MD, PhD¹, Regis Peffault De Latour, MD, PhD^{21*} and Ibrahim Yakoub-Agha, MD, PhD²²

¹Hematology and Cellular Therapy, Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France

²Hematology, CHU Caen, Caen, France

³Biostatistics, EBMT LWP Office, Paris, France

⁴Hematology, Institut Paoli-Calmettes, Marseille, France

⁵Hematology, AP-HP Hopital Saint-Louis, Paris, France

⁶Hematology, CHU Nantes, Nantes, France

⁷Hematology, University Hospital of Bordeaux, Pessac, France

⁸Hematology, CHU Saint Eloi Montpellier, Montpellier, France

⁹Institut Universitaire du cancer, Oncopole IUCT, Toulouse, France

¹⁰Hematology, Hospices Civils de Lyon - Université de Lyon, Pierre-Bénite, France

¹¹Hematology, CHU Tours, Tours, France

¹²Clinical Hematology, Centre Henri Becquerel, Rouen, France

¹³Division of Hematology, Institut Gustave Roussy, Villejuif, France

¹⁴Hematology, CHU Nancy, Nancy, France

¹⁵Hematology, CHU Angers, Angers, France

¹⁶Hematology Department, Pitie-Salpetriere Hospital, Paris, France

¹⁷Hematology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France

¹⁸Hematology, CHU Grenoble Alpes, Grenoble, France

¹⁹Hematology, CHU Limoges, Limoges, France

²⁰Hematology, CHU Rennes, Rennes, France

²¹Hematology - Bone Marrow Transplantation, Saint Louis Hospital, Paris, France

²²Service des Maladies du Sang, Hopital Claude Huriez, CHRU Lille, Lille, France

2861 Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Philippe Attias^{1*}, Aline Renneville, MD^{2*}, Xavier Thomas, MD, PhD³, Cecile Bally^{4*}, Sandrine Hayette^{5*}, Hassan Farhat, MD^{6*}, Virginie Eclache, MD^{7*}, Alice Marceau^{8*}, Bruno Cassinat, PharmD, PhD^{9*}, Jean Feuillard, MD- PhD, Pr^{10*}, Christine Terré, PharmD, PhD^{11*}, **Eric Delabesse**, PharmD, PhD^{12*}, Sophie Park, MD, PhD^{13*}, Julie Lejeune^{14*}, Sylvie Chevret, MD, PhD^{15*}, Lionel Ades, MD, PhD¹⁶, Claude Preudhomme, MD, PhD² and Pierre Fenaux, MD, PhD^{17,18}

¹Service d'Hématologie Senior, Hôpital Saint Louis, Paris, France

²Hematology Laboratory, CHRU Lille, Lille, France

³CHU, Lyon, France

⁴Hopital Saint Louis, Paris, France

⁵Laboratory of Hematology, Centre Hospitalier Lyon-Sud, Lyon, France

⁶Hematology Department, CH Versailles, Versailles, France

⁷Hematology Laboratory, CHU Avicenne, Bobigny, France

⁸Haematology Laboratory, CHRU Lille, Lille, France

⁹Service de Biologie Cellulaire, AP-HP, Hôpital Saint-Louis, Paris, France

¹⁰Laboratoire d'hématologie, CHU Limoges, Limoges, France

¹¹Hematology Laboratory, Centre Hospitalier Andre Mignot, Versailles, France

¹²Laboratoire d'Hématologie, CHU de Toulouse, Toulouse, France

¹³CHU Grenoble Alpes, University Clinic of hematology, Grenoble, France

¹⁴Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Paris, France

¹⁵Biostatistic, Saint-Louis Hospital, APHP, Paris, France

¹⁶Service d'Hématologie Séniors,, St Louis hospital, University Paris 7, Paris, France

¹⁷Groupe Francais des myélodysplasies (GFM), Paris, France

¹⁸Saint-Louis Hospital, University Paris 7, Paris, France

788 Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Chronic Myeloid Leukemia: Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 632. Chronic Myeloid Leukemia: Therapy: TKI-Discontinuation

Thomas Pagliardini^{1*}, Franck E. Nicolini, MD, PhD^{2,3}, Stephane Giraudier, MD, PhD^{4*}, Philippe Rousselot^{5*}, Gabriel Etienne, MD, PhD^{2,6*}, **Françoise Huguët, MD^{2,7*}**, Agnes Guerci-Bresler, MD, PhD^{2,8*}, Bruno R. Varet, MD PhD⁹, Martine Escoffre, MD^{10*}, Stephane Morisset, Stat^{11*}, Francois-Xavier Mahon^{12,13} and **Laurence Legros, MD, PhD^{2,14*}**

¹CHU de Nice, Nice, France

²Fi-LMC group, Pessac, France

³Centre Hospitalier Lyon Sud, Pierre-Bénite, France

⁴Hôpital Henri-Mondor, Créteil, France

⁵Centre Hospitalier, Versailles, FRA

⁶Hematology Department, Institut Bergonie, Bordeaux, France

⁷Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

⁸Hematology Department, CHU Brabois, Nancy, France

⁹Hematology Department, Hopital Necker-Enfants Malades / Paris Sorbonne Cité, Paris, France

¹⁰CHU Rennes, Rennes, France

¹¹Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

¹²Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France

¹³FILMC group, Bordeaux, France

¹⁴Institut de Biologie Valrose, iBV, Nice, France

3705 A Retrospective Analysis of *Pneumocystis Jirovecii* Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III

Laurie H Sehn, MD¹, Michael Hallek², Wojciech Jurczak³, Jennifer R. Brown⁴, Paul M. Barr⁵, John Catalano⁶, Steven E. Coutre, MD⁷, Richard R. Furman⁸, Nicole Lamanna⁹, **Ysebaert Loïc^{10*}**, Andrew D. Zelenetz¹¹, Jeffrey P. Sharman¹², Sven DeVos^{13*}, Adeboye Henry Adewoye¹⁴, Yeonhee Kim^{14*}, Ian W. Flinn, MD, PhD¹⁵ and Gilles A. Salles¹⁶

¹Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada

²Dep. 1 of Internal Medicine, University of Cologne, Cologne, Germany

³Department of Haematology, Jagiellonian University, Kraków, Poland

⁴CLL Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁵Wilmot Cancer Institute, University of Rochester, Rochester, NY

⁶Frankston Hospital and Monash University, Frankston, Australia

⁷Stanford University School of Medicine, Stanford, CA

⁸Weill Cornell Medical College, New York, NY

⁹Leukemia Service, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY

¹⁰Service d'Hématologie, Cancer Research Center of Toulouse, Toulouse, France

¹¹Memorial Sloan Kettering Cancer Center, New York, NY

¹²Willamette Valley Cancer Institute and Research Center, US Oncology Research, Springfield, OR

¹³David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

¹⁴Gilead Sciences, Inc., Foster City, CA

¹⁵Sarah Cannon Research Institute, Nashville, TN

¹⁶Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Université Claude Bernard Lyon 1, Lyon, France

347 Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Myelodysplastic Syndromes—Clinical Studies

Program: Oral and Poster Abstracts

Type: Oral

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Higher Risk MDS Clinical Studies

Marie Sebert, MD^{1,2*}, Cecile Bally^{3*}, Pierre Peterlin, MD^{4*}, **Odile Beyne-Rauzy, MD, PhD^{5*}**, Laurence Legros, MD, PhD^{6*}, marie Pierre Gourin, MD, PhD^{7*}, Laurence Sanhes, MD^{8*}, Eric Wattel, MD PhD⁹, Emmanuel Gyan, MD, PhD¹⁰, Sophie Park, MD, PhD^{11*}, Aspasia Stamatoullas, MD^{12*}, Anne Banos^{13*}, Kamel Laribi, MD^{14*}, Simone Jueliger, PhD^{15*}, Luke Bevan^{16*}, Cendrine Chaffaut^{17*}, Rosa Sapena^{18*}, Benedicte Samey^{1*}, Fatiha Chermat^{1*}, Sylvie Chevret^{19*}, Lionel Ades, MD, PhD²⁰ and Pierre Fenaux, MD, PhD²¹

¹GFM, Hôpital Saint Louis, Paris, France

²Service d'Hématologie Séniors, Hôpital St Louis, Université Paris 7, Paris, France

³Hopital Saint Louis, Paris, France

⁴HOPITAL HOTEL DIEU ET HME, NANTES CEDEX 1, FRA

⁵Service de medecine Interne, CHU Purpan, Toulouse, France

⁶Hematology department, Hopital Archet 1, CHU Nice, Nice, France

⁷CHU, Limoges, France

⁸Department of Hematology, CH Perpignan, Perpignan, France

⁹Lyon I University, Lyon, France

¹⁰Service d'Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire, Tours, France

¹¹CHU Grenoble Alpes, University Clinic of hematology, Grenoble, France

¹²Clinical Hematology, Centre Henri Becquerel, Rouen, France

¹³Centre Hospitalier de la Cote basque, Bayonne, France

¹⁴Centre Hospitalier, Le Mans, France

¹⁵ASTEX pharmaceuticals, Cambridge, GBR

¹⁶Astex Pharmaceutical, Cambridge, United Kingdom

¹⁷Departement de biostatistiques, hôpital Saitn-Louis, Paris, France

¹⁸Clinical Hematology, CHU Cochin, Paris, France

¹⁹Statistics St-Louis Hospital, Paris 7, Paris, France

²⁰Service d'Hématologie Séniors,, St Louis hospital, University Paris 7, Paris, France

²¹Saint-Louis Hospital, University Paris 7, Paris, France

4060 Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Tim Somerville, MD PhD¹, Olga Salamero, MD^{2*}, Pau Montesinos, MD, PhD^{3*}, Christophe Willekens, MD^{4*}, Jose Antonio Perez Simon, MD^{5*}, Arnaud Pigneux, MD^{6*}, **Christian Recher, MD, PhD⁷**, Rakesh Popat^{8*}, Cesar Molinero, MD, PhD^{9*}, Christina Mascaro, PhD^{9*}, Tamara Maes, PhD^{10*} and Francesc Bosch, MD, PhD¹¹

¹The Christie NHS Foundation Trust, Manchester, United Kingdom

²Hospital Universitari Vall d'Hebron, Barcelona, Spain

³Hematology, Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain

⁴Clinical Hematology, Gustave Roussy Cancer Center, Villejuif, France

⁵Hospital Universitario Virgen del Rocío, Seville, Spain

⁶Hôpitaux du Haut Lévéque CHU Bordeaux, Pessac, France

⁷Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole - CHU de Toulouse, Toulouse, France

⁸Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

⁹Oryzon Genomics, Barcelona, Spain

¹⁰Oryzon Genomics, Cornella De Llobregat, ESP

¹¹Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain

2541 A Multicenter Study Evaluating the Safety of Romiplostim at Maximal Dosage for Emergency Bleeding Situations in Immune Thrombocytopenia

Disorders of Platelet Number or Function

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster II

Mathilde Roumier, MD^{1*}, Louis Terriou, MD^{2*}, Mohamed Hamidou, MD, PhD^{3*}, Antoine Dossier, MD^{4*}, Anne Sophie Morin, MD^{5*}, Virginie Zarrouk, MD^{6*}, Mickael Ebbo, MD^{7*}, **Guillaume Moulis, MD, PhD^{8*}**, Lionel Galicier, MD^{9*}, Sylvain Audia, MD, PhD^{10*}, Laetitia Languille^{11*}, Marie Goussef, MD^{12*}, Solène Poutrel, MD^{13*}, Marc Michel, MD, ^{14*}, Bertrand Godeau, MD, PhD^{14*} and **Matthieu Mahévas, MD, PhD^{11*}**

¹Internal Medicine, French referral center for adult's immune cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France

²Department of Internal Medecine, clinical immunology, Hôpital HURIEZ CHRU Lille, Lille, France

³Department of Internal Medicine, Hôtel Dieu University Hospital, Nantes, France

⁴Department of internal Medicine, Hôpital Bichat, Paris, France

⁵Department of internal medicine, Hôpital Jean Verdier, Bondy, France

⁶Deptment of internal medicine, Hôpital Beaujon, Clichy, France

⁷Department of internal medicine, Assistance publique Hôpitaux de Marseille, marseille, France

⁸Internal Medicine Department, Toulouse University Hospital; UMR 1027 Inserm-, Toulouse, France

⁹St-Louis University Hospital, Paris, France

¹⁰Department of internal medicine, Dijon university hospital, Dijon, FRA

¹¹Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri-Mondor, APHP, Créteil, France

¹²Deptment of Internal Medicine, Centre hospitalier Bretagne Atlantique, Vannes, France

¹³Department of Internal Medicine, Lyon university hospital, Lyon, France

¹⁴Internal Medicine, French referral center for adult's immune cytopenia, Henri Mondor Hospital, AP-HP, UPEC University, Créteil, France

356 A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Insights from Molecular Alterations and Alternate Splicing

Anil Aktas Samur, PhD^{1,2*}, Mehmet Kemal Samur, PhD^{3*}, Stephane Minvielle, PhD^{4*}, Florence Magrangeas^{5,6*}, Mariateresa Fulciniti, PhD⁷, Raphael Szalat^{8*}, Paul G. Richardson, MD⁹, Kenneth C. Anderson, MD¹⁰, **Michel Attal¹¹**, Philippe Moreau^{12*}, Giovanni Parmigiani, PhD^{3*}, **Hervé Avet-Loiseau^{13*}** and Nikhil C Munshi, MD^{7,14}

¹Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA

²Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA

³Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

⁴Unité Mixte de Genomique du Cancer, Centre Hospitalier Universitaire de Nantes, Nantes, France

⁵Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche Thérapeutique de l'Université de Nantes (IRT-UN), Nantes, France

⁶Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France

⁷The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁸Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁹Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

¹⁰Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

¹¹Institut Universitaire du Cancer-Oncopole, Toulouse, France

¹²Department of Hematology, Nantes University Hospital, Nantes, France

¹³Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale, Toulouse, France

¹⁴VA Boston Healthcare System, Boston, MA

236 The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Progression

Raphael Szalat^{1*}, Niccolo Bolli, MD^{2,3*}, Francesco Maura^{2,4*}, Stephane Minvielle, PhD^{5*}, Dominik Gloznic^{4*}, Florence Magrangeas^{6*}, Philippe Moreau^{7*}, Anthony Fullam^{4*}, Mehmet K. Samur, PhD^{8*}, Patrick Tarpey^{4*}, Nicholas Anthony DaSilva, BS⁹, Helen Davies^{4*}, Inigo Martincorena^{4*}, Kevin J. Dawson^{4*}, Jose Tubio, PhD^{4*}, Jorge Zamora^{4*}, Yu-Tzu Tai, PhD¹⁰, Kenneth C. Anderson¹⁰, David Wedge^{4,11*}, **Hervé Avet-Loiseau^{12*}**, Peter J Campbell, MD, PhD^{13*} and Nikhil C Munshi, MD¹⁰

¹Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

²Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

³Wellcome Trust Sanger Institute, Cambridge, United Kingdom

⁴Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

⁵Unité Mixte de Genomique du Cancer, Centre Hospitalier Universitaire de Nantes, Nantes, France

⁶Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche Thérapeutique de l'Université de Nantes (IRT-UN), Nantes, France

⁷Department of Hematology, Nantes University Hospital, Nantes, France

⁸The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁹University of Rhode Island, Kingston, RI

¹⁰Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

¹¹University of Oxford, Big Data Institute, Oxford, United Kingdom

¹²UC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

¹³Cancer genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

4643 Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia Transplanted in First Complete Remission from HLA-Identical Related or Unrelated Donors: A Retrospective Study on Behalf of the ALWP of the EBMT

Clinical Autologous Transplantation: Results

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster III

Giorgia Battipaglia^{1,2*}, **Annalisa Ruggeri**^{2*}, **Myriam Labopin**, MD^{2,3,4*}, **Liisa Volin**, MD, PhD⁵, **Didier Blaise**, MD, PhD⁶, **Gerard Socié**, MD, PhD^{7*}, **Noel Milpied**, MD⁸, **Jan J. Cornelissen**, MD, PhD⁹, **Ardeshir Ghavamzadeh**, Professor¹⁰, **Anne Huynh**, MD^{11*}, **Wu Depei**^{12*}, **Ibrahim Yakoub-Agha**, MD, PhD¹³, **Johan Maertens**, MD, PhD^{14*}, **Patrice Chevallier**, MD, PhD^{15*}, **Mohamad Mohty**, MD, PhD^{2,16,17} and **Arnon Nagler**, MD, MSc^{3,18}

¹Hematology Department, Federico II University, Naples, Italy

²Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

³Acute Leukemia Working Party of the EBMT, Paris, France

⁴Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France, Paris, France

⁵Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland

⁶Programme de Transplantation & Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

⁷Hopital St. Louis, Dept. of Hematology – BMT, Paris, France

⁸Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Haut-Lévêque, Bordeaux, France

⁹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

¹⁰Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

¹¹Institut Universitaire du Cancer Toulouse, Oncopole, Toulouse, France

¹²First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, China

¹³Hematology, Hôpital HURIEZ UAM allogreffe de CSH, CHRU, Lille, France

¹⁴Department of Hematology, University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium

¹⁵Department of Hematology, Nantes University Hospital, Nantes, France

¹⁶Hematology and Cellular Therapy, Hospital Saint-Antoine, Paris University UPMC, INSERM U938, Paris, France

¹⁷EBMT, Acute Leukemia Working Party, Paris, France

¹⁸Division of Hematology, Sheba Medical Center, Ramat Gan, Israel

3245 Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II

Mauricette Michallet, MD, PhD¹, **Colette Chapuis-Cellier**, Dr^{2*}, **Christine Lombard**, Dr^{2*}, **Mohamad Sobh**, PharmD^{3*}, **Thomas Dejoie**, PharmD^{4*}, **Helene Caillon**, PharmD^{5*}, **Michel Attal**⁶, **Philippe Moreau**^{7*} and **Hervé Avet-Loiseau**^{8*}

¹Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon, France

²Centre Hospitalier Lyon-Sud, Lyon, France

³Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

⁴Biochemistry Laboratory, Centre Hospitalier Universitaire-Nantes, Nantes, France

⁵Biochemistry Laboratory, Nantes University Hospital, Nantes, France, Nantes, France

⁶Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

⁷Department of Hematology, Nantes University Hospital, Nantes, France

⁸IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

2892 Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Cecile Bally^{1*}, Jacqueline Lehmann-Che^{1*}, Bruno Cassinat, PharmD, PhD^{2*}, Lionel Ades, MD, PhD³, Eric Letouze^{4*}, Pierre Hirsch^{5,6*}, Marie-Joelle Mozziconacci^{7*}, Sophie Raynaud, MD⁸, **Eric Delabesse**, PharmD, PhD^{9*}, Madalina Uzunov, MD^{10*}, Mathilde Hunault, MD, PhD^{11*}, Eric Lippert, PhD^{12*}, Hélène Lapillonne, MD, PhD^{13*}, Christophe Ferrand, PhD¹⁴, Carine Gervais, MD^{15*}, Nathalie Gachard, PhD^{16*}, Agnès Guerci, MD, PhD^{17*}, Pierre Fenaux, MD, PhD¹⁸ and Hugues de The, MD, PhD¹⁹

¹Hopital Saint Louis, Paris, France

²Service de Biologie Cellulaire, AP-HP, Hôpital Saint-Louis, Paris, France

³Service d'Hématologie Séniors,, St Louis hospital, University Paris 7, Paris, France

⁴Integragen/GECO, Paris, France

⁵INSERM U938, Paris, France

⁶Service d'Hematologie et de Therapie cellulaire, Hopital St Antoine, Paris, France

⁷Department of Cancer Biology, Institut Paoli Calmettes, Marseille, France

⁸Laboratoire d'Oncohematologie, Hopital Pasteur, Nice, France

⁹Laboratory of Hematology, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France

¹⁰Hematology Department, Pitie-Salpetriere Hospital, Paris, France

¹¹Hematology, Medical University Hospital, Angers, France

¹²Laboratory of hematology, University Hospital Center of Bordeaux, Pessac, France

¹³Hematology Laboratory, Trousseau Hospital, HUEP, APHP, Paris, France

¹⁴EFS BFC, Inserm UMR1098, University hospital Besancon, University Franche Comte, Besancon, France

¹⁵LRCHA, Strasbourg - Mulhouse, France

¹⁶limoges, limoges, France

¹⁷Hématologie Clinique, CHU Nancy-Brabois, Vandoeuvre, France

¹⁸Saint-Louis Hospital, University Paris 7, Paris, France

¹⁹Univ. of Paris, Hospital St. Louis, Paris, France

4428 Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III

Helene Caillon, PharmD^{1*}, **Michel Attal**², **Hervé Avet-Loiseau**^{3*}, Cyrille Touzeau, MD^{4*}, Philippe Moreau^{5*} and Thomas Dejoie, PharmD^{6*}

¹Biochemistry Laboratory, Nantes University Hospital, Nantes, France, Nantes, France

²Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

³IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

⁴Department of hematology, Nantes university Hospital and UMR892 INSERM, Nantes, France

⁵Department of Hematology, Nantes University Hospital, Nantes, France

⁶Biochemistry Laboratory, Centre Hospitalier Universitaire-Nantes, Nantes, France

512 Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission: An Analysis By the Acute Leukemia Working Party of the EBMT

Clinical Autologous Transplantation: Results

Program: Oral and Poster Abstracts

Type: Oral

Session: 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation

Sebastian Giebel^{1*}, Myriam Labopin, MD^{2,3*}, Michael Potter⁴, Xavier Poiré, MD^{5*}, Henrik Sengeloev, MD^{6*}, Gerard Socié, MD, PhD^{7*}, **Anne Huynh, MD**^{8*}, Boris V Afanasyev, Professor^{9*}, Urs Schanz, MD¹⁰, Olle Ringden^{11*}, Peter Kalhs, MD¹², Dietrich W. Beelen, Prof. Dr. med.¹³, Antonio M. Campos, MD¹⁴, Tamás Masszi, MD, PhD¹⁵, Mohamad Mohty, MD, PhD^{2,16} and Arnon Nagler^{*}, MD^{2,17}

¹Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

²Acute Leukemia Working Party of the EBMT, Paris, France

³Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France

⁴The Royal Marsden Center, London, United Kingdom

⁵Section of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium

⁶Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

⁷Hopital St. Louis, Dept.of Hematology – BMT, Paris, France

⁸Institut Universitaire du Cancer, Oncopole IUCT, Toulouse, France

⁹R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, Academician

I.P.Pavlov First St.Petersburg State Medical University, Saint-Petersburg, Russia

¹⁰Division of Hematology, University Hospital Zurich, Zurich, Switzerland

¹¹Karolinska Institutet, Stockholm, Sweden

¹²Medical University of Vienna, Vienna, AUT

¹³Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany

¹⁴Serviço de Transplantação de Medula Óssea, Instituto Português de Oncologia, Porto, Portugal

¹⁵St. István & St. Laszlo Hospital Semmelweis University St. Laszlo Campus, Budapest, Hungary

¹⁶Department of Haematology, EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France

¹⁷Chaim Sheba Medical Center, Tel-Hashomer, Israel

376 Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Clinical Insights from Multiple Myeloma Biology and Biomarkers

Thomas Dejoie, PharmD^{1*}, Michel Attal², Philippe Moreau^{3*} and Hervé Avet-Loiseau^{4*}

¹Biochemistry Laboratory, Centre Hospitalier Universitaire-Nantes, Nantes, France

²Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

³Department of Hematology, Centre Hospitalier Universitaire-Nantes, Nantes, France

⁴IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

Introduction

3242 The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study

CLL: Therapy, excluding Transplantation

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster II

Philip A Thompson, MBBS^{1*}, Vincent Levy, MD, PhD^{2*}, Constantine S. Tam, MBBS³, Chadi al Nawakil, MD^{4*}, Francois Xavier Goudot, MD^{5*}, Anne Quinquenel, MD^{6*}, Loic Ysebaert, MD, PhD^{7*}, Anne-Sophie Michallet, MD^{8*}, Marie Sarah Dilhuydy, MD^{9*}, Eric W Van Den Neste, MD, PhD¹⁰, Jehan Dupuis, MD^{11*}, Michael Keating, MBBS¹, Christophe Meune, MD, PhD^{12*} and Florence Cymbalista, MD, PhD¹³

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²Hôpital Avicenne, Bobigny, France

³Peter MacCallum Cancer Centre & St. Vincent's Hospital, Melbourne, Australia

⁴CRC, Hôpital Avicenne, Bobigny, France

⁵Service de Cardiologie, Hôpital Avicenna, Bobigny, France

⁶Hopital Robert Debre, Reims, France

⁷Haematology dept, IUCT oncopole, Toulouse, France

⁸Centre Léon Bérard, Lyon, France

⁹Hôpital Haut-Lévêque, Pessac, France

¹⁰Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium

¹¹Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor, CRETEIL, France

¹²Service de Cardiologie, Hôpital Avicenna, bobigny, France

¹³Service d'hématologie biologique, Hôpital Avicenne, Bobigny, France

2899 Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT

Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis

Program: Oral and Poster Abstracts

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II

Jonathan Canaani, MD¹, Eric Beohou^{2*}, Myriam Labopin^{3*}, Gerard Socie, MD, PhD⁴, Anne Huynh, MD^{5*}, Liisa Volin, MD, PhD⁶, Jan J. Cornelissen, MD, PhD⁷, Noel Milpied, MD PhD⁸, Tobias Gedde-Dahl^{9*}, Eric Deconinck, MD, PhD¹⁰, Jeremy Delage, MD^{11*}, Didier Blaise, MD, PhD¹², Mohamad Mohty, MD, PhD¹³ and Arnon Nagler¹⁴

¹Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel

²Hopital Saint-Antoine, EBMT, Acute Leukemia Working Party and Registry, Paris, France

³EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France

⁴St-Louis Hospital, Paris, France

⁵Institut Universitaire du cancer, Oncopole IUCT, Toulouse, France

⁶Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland

⁷Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

⁸Service d'Hématologie et de Thérapie Cellulaire, CHU Haut-Leveque and University of Bordeaux, Bordeaux, France

⁹Dept of Internal Medicine, Oslo University Hospital, Oslo, Norway

¹⁰Department of Hematology, CHU Besancon, Besancon, France

¹¹Service d'Hématologie Clinique et Therapie Cellulaire, CHU de Bordeaux, Pessac, France

¹²Programme de Transplantation et Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France

¹³Hôpital Saint-Antoine, EBMT, Acute Leukemia Working Party and Registry, Paris, France

¹⁴Chaim Sheba Medical center and EBMT Acute Leukemia Working Party, Tel-Hashomer and Paris, Israel

2008 Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study

Myelodysplastic Syndromes—Clinical Studies

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Christian Rose, MD,¹ Olivier Fitoussi, MD^{2*}, Emmanuel Gyan, MD, PhD³, Maya Hacini, MD^{4*}, Shanti Amé, MD^{5*}, Bernadette Corront, MD^{6*}, Odile Beyne-Rauzy, MD, PhD^{7*}, Didier Innocent Adiko, MD^{8*}, Elena-Anca Loppinet, MD^{9*}, Nadia Ali-Ammar, MD^{10*}, Eric Wattel, MD PhD¹¹, Francois Dreyfus, MD^{12*} and Stéphane Cheze, MD, PhD^{13*}

¹Hématologie clinique, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France

²Polyclinique Bordeaux Nord-Aquitaine, Bordeaux, France

³Service d'Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire, Tours, France

⁴service d'hematologie, Chambéry, France

⁵Hematology department, Hôpital Civil, CHU Strasbourg, Strasbourg, France

⁶Centre Hospitalier Annecy-Gennevois,, Annecy, France

⁷Service de medecine Interne, CHU Purpan, Toulouse, France

⁸Hôpital Robert Boulin, Libourne, Libourne, FRA

⁹service d'hématologie, CH Metz, Metz, France

¹⁰service d'hématologie, CH Troyes, Troyes, France

¹¹Lyon I University, Lyon, France

¹²CHU Cochin, Hematology, Paris, France

¹³Institut d'Hématologie de Basse-Normandie, CHU Caen Hôpital Côte de Nacre, Caen, France

4462 Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy

Program: Oral and Poster Abstracts

Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III

Xiu Ly Song^{1*}, Raphaël Szalat, MD^{2,3*}, Alexis Talbot, MD^{4*}, HaiVu Nguyen, PhD^{1*}, Mehmet K. Samur, PhD^{5,6*}, David Mosen-Ansorena, PhD^{7,8*}, Nikhil C. Munshi, MD⁹, Stephane Minvielle, PhD^{10*}, Hervé Avet-Loiseau^{11*}, Wendy Cuccuini, MD, PhD^{12*}, Jean-Paul Fermand, MD^{1,13}, Bertrand Arnulf, MD, PhD^{1,14*} and Jean-Christophe Bories^{15*}

¹INSERM, UMR 1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

²Medical Oncology, Harvard Medical School, Boston, MA

³Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁴INSERM, UMR 1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

⁵The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁶The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁷Harvard School of Public Health, Boston, MA

⁸Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

⁹Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

¹⁰Unité Mixte de Genomique du Cancer, Centre Hospitalier Universitaire de Nantes, Nantes, France

¹¹Institut Universitaire du Cancer and University Hospital, Unité de Génomique du Myélome, Toulouse, France

¹²Haematology Laboratory, Saint-Louis Hospital, APHP, Paris, France

¹³Immuno-Hematology Unit, Saint-Louis Hospital, Paris, France

¹⁴INSERM, UMR 1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, Paris, France

¹⁵INSERM, UMR 1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, FRA

4563 Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in First Complete Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party

Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution

Program: Oral and Poster Abstracts

Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution Poster III

Yishai Ofran, MD^{1,2}, Eric Beohou^{3*}, Myriam Labopin^{4*}, Didier Blaise, MD, PhD⁵, Jan J. Cornelissen, MD, PhD⁶, Marco R De Groot, MD, PhD⁷, Gerard Socié, MD, PhD^{8*}, Anne Huynh, MD^{9*}, Johan Maertens, MD, PhD^{10*}, Frederic Baron, MD, PhD¹¹, Mohamad Mohty, MD, PhD¹² and Arnon Nagler^{3,13}

¹Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel

²Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

³Hopital Saint-Antoine, EBMT, Acute Leukemia Working Party and Registry, Paris, France

⁴EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France

⁵Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France

⁶Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

⁷Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

⁸Hopital St. Louis, Dept. of Hematology – BMT, Paris, France

⁹Institut Universitaire du Cancer, Oncopole IUCT, Toulouse, France

¹⁰Department of Hematology, University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium

¹¹Hematology & GIGA Research, University of Liege, Liege, Belgium

¹²Department of Haematology, EBMT Paris study office / CEREST-TC / Saint Antoine Hospital, Paris, France

¹³Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, and Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel

2070 Evaluation of the Concordance of Two Free Light Chains Assays to Identify High Risk Smoldering Myeloma Patients.

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Caroline Moreau^{1*}, Emmanuel Rouger^{1*}, Basile Henriot^{2*}, Martine Escoffre^{3*}, Martine Sebillot^{2*}, Thierry Lamy³, Stéphane Minvielle^{4*}, Hervé Avet-Loiseau^{5*} and Olivier Decaux, MD, PhD^{2*}

¹Biochemistry, University Hospital CHU Rennes, Rennes, France

²Internal Medicine, University Hospital CHU Rennes, Rennes, France

³Hematology, University Hospital CHU Rennes, Rennes, France

⁴UMR 892 Inserm - 6299 CNRS, Nantes, France

⁵Institut Universitaire du Cancer and University Hospital, Unité de Génomique du Myélome, Toulouse, France

195 RNA-Seq De Novo Assembly of Clonal Immunoglobulin Rearrangements Identifies Interesting Biology and Uncovers Prognostic Features in Multiple Myeloma

Myeloma: Biology and Pathophysiology, excluding Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Prognostic Factors

David Mosen-Ansorena, PhD^{1,2*}, Rachael Bashford-Rogers, PhD^{3*}, Niccolo Bolli, MD^{4,5*}, Stéphane Minvielle, PhD^{6*}, Florence Magrangeas^{6*}, Kenneth C Anderson, MD⁷, Hervé Avet-Loiseau^{8*}, Giovanni Parmigiani, PhD^{2*} and Nikhil C Munshi, MD^{9,10}

¹Harvard School of Public Health, Boston, MA

²Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

³Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom

⁴Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

⁵Wellcome Trust Sanger Institute, Cambridge, United Kingdom

⁶Unité Mixte de Génomique du Cancer, Centre Hospitalier Universitaire de Nantes, Nantes, France

⁷Dana-Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA

⁸IUC-Oncopole, Unité de Génomique du Myélome, Toulouse, France

⁹VA Boston Healthcare System, Boston, MA

¹⁰The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

